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1. SUMMARY 
 
Skin is the largest organ of the human body and protects it from detrimental 
effects of the surrounding environment. As skin is directly exposed to the outer 
environment, it frequently occurs that it is destroyed by accidents. Large full-
thickness skin defects may result from burns but also from the surgical excision of 
congenital giant nevi or scar tissue. The treatment of large (> 40% total body surface 
area) full-thickness wounds represents a major challenge, as donor sites for 
autologous skin transplantation often are very limited, and transplantation of 
autologous split-thickness skin (the present gold standard of treatment) can lead to 
severe scarring, especially in children. These problems could be significantly reduced 
applying a bio-engineered autologous dermo-epidermal skin substitute. The Tissue 
Biology Research Unit (TBRU) has shown that collagen type I hydrogels are a 
promising scaffold for skin tissue engineering in pre-clinical models. As collagen 
hydrogels show weak mechanical properties, the first part of my work aimed on 
engineering human dermo-epidermal skin substitutes based on collagen type I 
hydrogels which were stabilised by both, plastic compression (established by a 
postdoctoral fellow in our team) and incorporated biodegradable meshes (established 
by me). I applied two different meshes of synthetic polymers to mechanically stabilise 
the collagen hydrogel. I was able to generate skin substitutes which developed into a 
near normal skin with a dermal compartment and a stratified epidermis in vitro and in 
vivo using a rat model. 
Another aspect of skin tissue engineering and the second part of my work 
concerns the youngest patients possible, the unborn human fetus. Fetal surgery to 
treat spina bifida has been convincingly demonstrated to markedly improve the 
perspectives of the patients. However, closure of skin defects of a fetus is a 
challenge, and in such cases engineered autologous fetal skin might help. In a first 
step towards engineering fetal skin, I could successfully apply human amniotic fluid 
derived cells in the dermal compartment of dermo-epidermal skin analogues, instead 
of the usually used human dermal fibroblasts, and succeeded in obtaining a well 
stratified, near normal epidermis. 
Bio-engineered dermo-epidermal skin substitutes could serve, additionally to 
their clinical application, for pre-clinical testing of newly designed medicinal products. 
SUMMARY 
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I therefore aimed in a third part of this work to evaluate whether the engineered skin 
substitutes can be used for pre-clinical testing of products designed for dermal 
regeneration. 
As clinical application of bio-engineered dermo-epidermal skin substitutes is a 
major goal of the TBRU, we last but not least aimed to fulfil all pre-clinical studies 
required for clinical trials. As the rat animal system only allows the transplantation of 
small, circular skin substitutes, we aimed in establishing a large animal model to 
proof the principle also in clinical relevant size and shape. Porcine skin shows the 
highest similarities to human skin and with this newly designed pig model 
transplantation of large, square autologous skin substitutes are possible.  
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2. ZUSAMMENFASSUNG 
 
 Die Haut ist das grösste Organ des menschlichen Körpers und schützt ihn vor 
schädlichen Umwelteinflüssen. Da die Haut direkt der Umwelt ausgesetzt ist, sind 
Verletzungen der Haut durch Unfälle häufig. Grossflächige tiefe Hautwunden  können 
bei Verbrennungen entstehen, oder aber auch bei der chirurgischen Entfernung von 
grossen angeborenen Nävi oder Narbengewebe. Die Behandlung von grossflächigen 
(> 40% der gesamten Körperoberfläche) tiefen Hautwunden stellt eine grosse 
Herausforderung dar, da Donorstellen für die Transplantation von autologer Haut 
häufig sehr limitiert sein können. Zudem kann die Transplantation von autologer 
Spalthaut, dem heutigen Goldstandard zur Behandlung, zu starker Narbenbildung 
führen. Dies wird vor allem bei Kindern häufig beobachtet. Diese Probleme könnten 
mit der Anwendung eines bio-engineerten autologen dermo-epidermalen 
Hautersatzes signifikant vermindert werden. Die Tissue Biology Research  Unit 
(TBRU) hat gezeigt, dass Hydrogele aus Kollagen Typ I eine vielversprechende 
Grundlage für die Herstellung von Hautsubstituten für präklinische Modelle sind. Da 
Hydrogele aus Kollagen aber schwache mechanische Eigenschaften haben, war das 
Ziel des ersten Teiles meiner Arbeit die Herstellung eines humanen dermo-
epidermalen Hautsubstitutes basierend auf einem Kollagen Typ I Hydrogel, welches 
sowohl durch plastische Kompression (entwickelt von einen Postdoktoranden aus 
dem Team) als auch mit einem biodegradierbaren Netz (von mir entwickelt) 
mechanisch stabilisiert wird. Ich habe zwei verschiedene Netze aus synthetischen 
Polymeren angewandt, um die Kollagengele zu stabilisieren. Damit konnte ich 
Hautsubstitute herstellen, welche sich sowohl in vitro als auch in vivo in einem 
Rattenmodell zu einer fast normalen Haut mit einem dermalen Kompartiment und 
einer stratifizierten Epidermis entwickelt  haben. 
 Ein weiterer Aspekt der Hautersatzforschung, und der zweite Teil meiner 
Arbeit, betrifft die jüngst möglichen Patienten, nämlich die ungeborenen 
menschlichen Feten. Es wurde überzeugend gezeigt, dass fetale Chirurgie für die 
Behandlung von Spina bifida die Aussichten der Patienten enorm verbessert. Das 
Schliessen eines Hautdefektes eines Fetus ist jedoch häufig eine Herausforderung 
und in solchen Fällen würden Hautsubstitute aus fetalen Zellen helfen. In einem 
ersten Schritt in Richtung eines fetalen Hautsubstitutes konnte ich erfolgreich 
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humane Zellen aus Amnionflüssigkeit in das dermale Kompartiment eines dermo-
epidermalen Hautsubstitutes einbringen, anstelle der üblicherweise verwendeten 
humanen dermalen Fibroblasten. Auch diese Hautsubstitute entwickelten eine gut 
stratifizierte Epidermis mit Eigenschaften ähnlich einer normalen Epidermis. 
 Bio-engineerte Hautsubstitute aus dem Labor könnten, zusätzlich zu einer 
klinischen Anwendung, auch für präklinische Studien für neu entwickelte 
Medizinalprodukte genutzt werden. Deshalb habe ich in einem dritten Teil dieser 
Arbeit evaluiert, ob die hergestellten Hautsubstitute für präklinische Tests für 
Produkte verwendet werden können, welche für die dermale Rekonstruktion 
entwickelt wurden. 
 Die klinische Anwendung der bio-engineerten dermo-epidermalen 
Hautsubstitute ist ein Hauptziel der TBRU. Daher war ein weiteres Ziel dieser Arbeit 
alle präklinischen Studien abschliessen zu können. Mit dem Rattenmodell können 
nur kleine, zirkuläre Hautsubstitute transplantiert werden. Unser Ziel war deshalb ein 
neues Tiermodell zu etablieren, welches die Transplantation von Hautsubstituten in 
klinisch relevanter Grösse und Form erlaubt. Die Haut von Schweinen weist die 
grösste Ähnlichkeit zu humaner Haut auf und mit dem neu etablierten 
Schweinemodell können grosse, rechteckige autologe Hautsubstitute transplantiert 
werden.  
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3. INTRODUCTION 
 
3.1 Human skin 
 
Human skin is the boundary of the human body to the environment. As such, 
skin has the most important role in protecting the body from environmental influences 
and maintaining the internal milieu, and therefore needs to resist the potentially 
harmful environmental influences. Amongst its wide range of functions, there are very 
diverse functions such as: 
 
• Anatomical barrier against irradiation, chemicals, physical forces, 
pathogens and microorganisms 
• Mediator of immune reactions via Langerhans cells that take up antigens 
and provide immunity by interacting with T cells 
• Help in thermoregulation via sweat secreting sweat glands and dilatation or 
contraction of blood vessels as response to heat/cold 
• Sensory function 
• Production of vitamin D via its synthesis from 7-dehydrocholesterol with 
the help of UV light 
 
In mammals, skin represents the largest organ. In adult humans it measures 
between 1.5 m2 and 2 m2 and weighs approximately 15% of the total body weight. 
Depending on the area of the body, the skin shows different characteristics which are 
adapted to the special needs of the local area, e.g. the thickness of the skin, which 
varies from 1 mm to 4 mm, and the distribution of skin appendages such as hairs, 
sweat glands and sebaceous glands (1). The outermost layer of the skin (Figure 1), 
which is in direct contact with the environment, is the stratified and keratinised 
epidermis. This layer contains no blood vessels and the cells of the epidermis, mainly 
keratinocytes, are nourished and supported by the underlying dermis, which is a 
collagen-rich connective tissue. The dominant cell type in the dermis is the fibroblast. 
The skin appendages such as hair follicles and sweat glands derive from the 
ectoderm, but reach down deep into the dermis. Underneath the dermis, the 
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subcutaneous tissue mainly consists of adipose tissue. This tissue serves as  a 
protection from injuries with its function as a cushion, serves as energy supply and 
insulates the body (2-3). 
 
 
 
Figure 1: The composition of human skin. Schematic view of the composition of the human skin, 
showing the two main layers as well as the most important skin appendages. (4) 
 
 
3.1.1 Epidermis 
 
The epidermis is a stratified epithelium. The main cell type of the epidermis, 
constituting about 90-95% of it, is the keratinocyte. Other cell types in the epidermis 
are melanocytes, Langerhans cells and Merkel cells. The epidermis undergoes 
constant renewal by the keratinocytes. Keratinocyte stem cells in the basal cell layer 
of the epidermis give rise to new keratinocytes which then, while undergoing 
additional steps of differentiation, migrate through the different epidermal layers 
towards the epidermal surface, until they reach the outermost layer as flattened, 
dead cells that are shed from the surface (1). The average thickness of the epidermis 
is about 100 µm, but high variations can be seen depending on their location in the 
body. The epidermis of palms and soles can be up to 1 mm thick, whereas the 
epidermis of the eyelid is only 50 µm thick. 
INTRODUCTION 
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Keratinocytes 
Keratinocytes (Figure 2) are the main cell type of the epidermis. They originate 
from the ectoderm and are arranged in the epidermis in continuous layers.  
 
 
   
Figure 2: Human keratinocytes in culture. The typical appearance of human primary epidermal 
keratinocytes on cell culture plastic visualised by 
a) light microscopy and 
b) immunofluorescence staining. The cells are positive for the human cytokeratin marker K5 (green). 
Scale bars 50 µm (a), 100 µm (b). (Figure b from L. Pontiggia) 
 
 
They show specific differentiation characteristics and morphology depending 
on their exact location within the different layers of the epidermis (Figure 3). 
Keratinocytes from the basal layer show a columnar morphology with an average 
size of 6-10 µm and a large nucleus, whereas keratinocytes from the stratum 
spinosum are larger with a size of 10 - 15 µm and polygonal in shape. The flattened 
keratinocytes from the granular layer have a diameter of 25 µm and are arranged 
parallel to the skin surface. The keratinocytes of the stratum corneum lost their 
nucleus, show a hexagonal shape when viewed from above and have a diameter of 
30-40 µm. (1,5) 
 
 
a b
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Figure 3: Schematic overview on the strata of the human epidermis. (6) 
 
 
Other cell types of the epidermis 
Melanocytes are neural crest-derived cells that reside in the basal layer of the 
epidermis at a ratio of about one melanocyte per five keratinocytes. They produce 
the skin pigment melanin, which is stored in melanosomes. The melanosomes are 
transported via dendrites and transferred to keratinocytes of the upper strata. One 
melanocyte supplies about 36 keratinocytes with melanin. In the keratinocytes, the 
melanin is located supra-nuclear to protect the nucleus from UV-light. Interestingly, 
the different skin colours seen in different ethnic groups do not result from different 
melanocyte numbers, but are a result of variations in melanocyte activity and most 
importantly variations in the ratio between the two main forms of melanin, the 
eumelanin and pheomelanin. (7) 
3-6% of the cells of the epidermis are the mobile Langerhans cells which are 
constituents of the immune system. They originate from haematopoietic precursors of 
the bone marrow and show a rounded morphology with dendrites. They reside in the 
epidermis as immature cells, which mature upon contact with an exogenous antigen. 
They take up the antigen, process it and present it in regional lymph nodes to naive 
T-cells (8). 
Merkel cells reside in the basal layer of the epidermis and are involved in 
sensory transduction. Their density is highly variable with a maximum in palmo-
plantar skin. They form synaptic junctions with dermal sensory axons (9). 
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Keratins 
 Keratins constitute up to 85% of a fully differentiated keratinocyte. These 
proteins are a type of intermediate filaments. Intermediate filaments are one class of 
the three major cytoskeletal proteins of eukaryotic cells (Table 1). They give structure 
and stability to the keratinocytes and are responsible for the mechanical strength of 
the vertebrate epidermis (10). In addition to their importance as cytoskeletal 
elements, recent studies showed that some keratins also have regulatory functions in 
intracellular signalling pathways, such as stress protection, wound healing and 
apoptosis, which suggest that they are involved in the refinement of epithelial 
functions (11-14). To fulfil all these functions, the cytoskeletal network they form is 
very dynamic and in a constant cycle of keratin intermediate filament assembly and 
disassembly (15-17). Certain mutations in keratin intermediate filaments are known 
to lead to blistering diseases (18). 
 
 
Table 1: Cytoskeletal proteins. Overview on the three main groups of cytoskeletal proteins found in 
eukaryotic cells. (19) 
 
Cytoskeleton class Fibre diameter Main function Examples 
Actin filaments 6 nm Cell motility Actin 
Intermediate 
filaments 10 nm Cell structure 
Keratins, vimentin, 
nuclear laminins 
Microtubules 23 nm Intracellular transport, mitotic spindle α-tubulin, β-tubulin 
 
 
 Keratins can be divided in two families based on their pH value. The acidic 
keratins type I include the keratins K9-K20 and four hair keratins (Ha1-Ha4). The 
group of the basic keratins type II includes the eight epithelial proteins K1-K8 and 
four hair keratins (Hb1-Hb4) (18). All the keratins share common protein-structural 
characteristics. The central α-helical rod domain (~310 amino acids) is flanked by 
non-helical head and tail domains of variable lengths. The first step in the assembly 
of keratin intermediate filaments is the formation of heterodimers, built from a type I 
keratin and a type II keratin, where the central rod domains are arranged in a parallel 
way. Two of these dimers assemble into a protofilament, and two protofilaments 
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interact to form the protofibril. Finally, four protofibrils form the 10 nm intermediate 
filament (Figure 4) (14,18). 
 
 
 
     
Figure 4: Intermediate filaments. Schematic representation of the alignment of the subunits of an 
intermediate filament. 
a) The arrows indicate the direction of the polypeptides. (20) 
 
 
Pairs of type I and type II keratins are expressed in most epithelial cells, 
whereas the type of pair is specific for the stages of development, differentiation and 
the body location. A summary of the most important keratins that can be found in 
human skin with their expression site is shown in Table 2. The keratins K8 and K18 
are the first keratins that appear in embryogenesis and they only can be found in the 
single-layered epithelium in a mammal embryo but not in adult, fully stratified human 
epidermis. (14,18,20) 
 
 
a b
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Table 2: Keratins. Overview of the most important keratins in human skin and their expression site. 
(14,18,20) 
 
Keratin Expression site Main partner 
K1 Suprabasally in most body regions K10 
K2e In granular keratinocytes K11 
K5 In basal cells that maintain their proliferative capacity K14 
K6 Transiently expressed during wound healing in suprabasal cells K16 
K9 Restricted to suprabasal palmar and plantar skin K1 
K10 Suprabasally in most body regions K1 
K14 In basal cells that maintain their proliferative capacity K5 
K15 In a subpopulation of basal cells K5 
K16 Transiently expressed during wound healing in suprabasal cells K6 
K19 In a subpopulation of K15 positive cells in the basal layer K7 
 
 
Structure of the human epidermis 
The epidermis of the human skin shows four or five distinct layers, depending 
on the body location. A schematic overview on the different strata of the epidermis is 
shown in Figure 3. 
The stratum basale (basal layer) is the layer of the epidermis in contact with 
the basement membrane. It mainly consists of one layer of tall, columnar, mitotically 
active keratinocytes. Cells from this layer proliferate to give rise to new keratinocytes 
that “migrate” upwards through all strata and eventually will be shed from the stratum 
corneum. The most important keratin filaments in the basal keratinocytes are fine 
bundles of K5 and K14, which allow enough flexibility for cell division and migration, 
but also K15 and K19 can be found (18,21). In contrast to many reports, we found 
that only K15 is exclusively expressed in basal keratinocytes of adult human skin, 
whereas K5 and K14 are also expressed in suprabasal layers (21). This may be 
different in mouse skin. In addition to keratinocytes there are also melanocytes in the 
stratum basale. Both cell types can be found in a ratio of about one (melanocyte) to 
five (keratinocytes). There are also Langerhans cells and Merkel cells (3,6). The 
basal keratinocytes are connected to the basement membrane via hemidesmosomes 
INTRODUCTION 
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(Figure 5) (22-23). In hemidesmosomes, the α6β4 integrin heterodimer can be found 
with several other associated proteins (22,24). 
 
 
 
Figure 5: Hemidesmosomes. 
a) Schematic overview on the location of hemidesmosomes in epithelia. 
b) Schematic model of the organisation of a hemidesmosome showing the protein-protein interactions 
of the main components. (23) 
 
 
The layer that gives structure and stability to the epidermis is the stratum 
spinosum (spinous layer). The suprabasal keratinocytes show a polyhedral 
morphology, whereas the keratinocytes in the upper layers of the stratum spinosum 
show a larger, flattened morphology. Additionally, the upper keratinocytes can 
already contain lamellar granules. The keratins in this stratum are present in thick 
bundles, which are organised concentrically around the nucleus and connect to the 
cytoplasmic plaques of the desmosomes (3). Cells in this layer adhere to each other 
via desmosomes (Figure 6) (22). These calcium-activated structures are composed 
of desmogleins and desmocollins, both belonging to the superfamily of cadherins 
(25). The types of desmogleins and desmocollins expressed in a desmosome 
depend on the localisation of the desmosome within a stratified epithelial sheet. In 
the lower spinous layers desmoglein 3 and desmocollin 3 can be found, whereas in 
the upper spinous layers the desmoglein and desmocollin types 1 are most 
expressed. Basal cells express mainly desmoglein 2 and desmocollin 2 (22). 
Desmosomes connect inside the cell to the keratin filaments through a series of 
a b
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adaptor molecules. Desmogleins and desmocollins connect to plakoglobin. 
Plakoglobin binds to desmoplakin which associates with the intermediate filaments 
(Figure 6). For maximal stability and cohesion, the desmogleins of a given cell attach 
to the desmocollins of the neighbouring cells (22,25). 
 
 
 
                  
Figure 6: Desmosomes. 
a) Structural elements of a desmosome. The cytoplasmic plaques (red) consist of intracellular anchor 
proteins. Keratin intermediate filaments (blue) are shown at the surface of the plaques. 
Transmembrane anchor proteins of the cadherin family (green) attach to the plaques and join cells to 
one another. 
b) Scheme of a desmosome showing the protein-protein interactions of its main components. 
Desmogleins (light green) and desmocollins (green) associate with plakoglobins (red) in the 
cytoplasm. Plakoglobins bind to desmoplakins (black), which in turn bind to intermediate filaments 
(blue). Modified from (19) 
 
 
The stratum granulosum (granular layer) consists of keratinocytes that are 
stratified and squamous. The cells are arranged in one to three layers and they 
contain the name-giving lamellar granules, organelles with a diameter of 100-300 nm. 
The lamellar granules contain precursors of the stratum corneum lipids, enzymes, 
and components needed for desquamation. They fuse with the plasma membrane 
and release the content to form a lipid-containing membrane that helps to maintain 
the impermeable skin barrier. The stratum granulosum is prominently formed in the 
skin of palms and soles. (3,26) 
a b
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Only in the thicker skin of palms and soles, the transparent stratum lucidum 
can be found, which is built by three to five layers of dead, flat keratinocytes. These 
keratinocytes are filled with the clear protein eleidin, an intermediate form of keratin. 
This stratum serves as an additional barrier at these most exposed sites and 
enhances the impermeability of skin. (27) 
The outermost layer, facing the environment, is the stratum corneum 
(cornified cell layer). This stratum of about 15-20 cell layers mainly consists of dead, 
flattened terminally differentiated keratinocytes (corneocytes) (28). The stratum 
corneum prevents water loss through its structure and the lipid matrix, and serves as 
a barrier to prevent harmful micro-organisms, such as bacteria, from entering the 
body (29). The thickness of the stratum corneum varies, depending on its localisation 
on the body. Areas more prone to injuries such as the sole of the feet and the palms 
of the hands exhibit a thicker stratum corneum, which may consist of up to hundreds 
of layers (30). 20% of the total mass of this stratum consist of a continuous lipid 
matrix, in which the terminally differentiated keratinocytes are embedded (31). The 
major lipid components are ceramides, fatty acids and cholesterol (31-32). 70-80% of 
the protein mass in these keratinocytes consists of loricrin and involucrin. The cells of 
the stratum corneum are continuously shed from the surface by a stringently 
controlled process, and are replaced by new keratinocytes derived from the lower 
strata (3,29,33). The time a basal cell needs to get up into the stratum corneum is up 
to four weeks (18). In the stratum corneum, desmosomes are modified to form the 
corneodesmosomes (34). These structures connect neighbouring corneocytes in the 
same layer, but also in adjacent layers. They are composed of desmoglein 1 and 
desmocollin 1 and additionally they contain specialised proteins such as 
corneodesmosin (35-36). For desquamation, corneodesmosomes are degraded by 
several hydrolytic enzymes in a specific pattern. (33) 
 
 
Development of the epidermis 
The first ectodermal covering of a human embryo early in gestation is the 
single-layered structure called periderm (Figure 7). The periderm appears to have a 
barrier function as tight junctions can be found. Additionally it is suggested that the 
periderm interacts with the amniotic fluid, as it has surface microvilli. Cells of the 
periderm are positive for keratin 8 and 18, but also for keratins 6, 16 and 17, which 
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normally are associated with wound healing and keratinocyte migration (37). During 
the first six weeks of development the coverage changes into a two-layered structure 
that consists of the outer periderm and the inner epidermis by receiving signals from 
the underlying mesenchyme which triggers and defines the program of differentiation. 
The ectoderm starts to proliferate and stratify. During gestational weeks nine and ten, 
expression of keratin 1 and keratin 10 can be detected in the epidermal cells. During 
the same time, other cell types migrate into the skin (38). In particular melanocytes 
from the neural crest, Langerhans cells from the thymus and bone marrow, and 
Merkel cells, believed to originate from epidermal keratinocytes (39-40). 
Soon after the stratification, during weeks 11-14 of gestation specialised 
mesenchymal cells called dermal placode cells form a dotted pattern beneath the 
basal layer. At the positions where these cells have contacted the basal layer of the 
epidermis, basal cells start to move downwards into the dermis and eventually form a 
hair follicle (25). Acceleration of the formation of the stratum corneum can be 
detected during week 20 - 40 of gestation, mainly in specific body sites such as the 
face, scalp, palms and soles (37-38). During the phase of rapid skin expansion, 
proliferation can be found suprabasally and not only restricted to basal cells. (25,41). 
 
 
 
 
Figure 7: Haematoxylin&Eosin staining of fetal and adult human skin. 
a) At week 14 of gestation, a basal layer can be detected as well as an intermediate cell layer and a 
periderm. 
b) The number of intermediate cell layers is increased at week 20 of gestation. Additionally, 
developing hair follicles are detectable. 
c) The adult epidermis is composed of a basal cell layer, followed by the spinous and granular cell 
layers and the stratum corneum which is the outermost layer. Scale bars 100 µm. (42) 
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3.1.2 Dermis 
 
The layer of the skin underneath the epidermis is the dermis. This skin layer 
consists of connective tissue that gives the elasticity and flexibility to the skin via its 
components, such as collagens, elastin and proteoglycans. This connective tissue is 
mainly composed of collagen types I and III (7). The dermis is compressible, and rich 
in blood vessels. It undergoes a continuous change of synthesis and degradation. 
The space between the fibres and the dermal cells is filled with macromolecules such 
as glycoproteins and proteoglycans. 
The most important cell type of the dermis is the fibroblast. But also cells of 
the immune system such as macrophages, T and B cells can be found. In addition 
there are blood vessels, lymphatic vessels and nerves (3). The dermis is innervated 
by two types of nerves; Parasympathic nerves release acetylcholine to the sweat 
glands via cholinergic neurons and nerves of the sympathicus nerves release 
norepinephrine to sweat glands, arteriolar smooth muscles and erector pili muscles 
(3). 
Two main layers of the dermis are identified, namely the papillary and reticular 
dermis (Figure 8) (43). The papillary dermis is the layer closest to the epidermis and 
has a variable thickness of approximately 300 - 400 µm, depending on age and 
anatomical localisation. The papillary dermis forms the dermal papillae, conical 
projections towards the epidermis. These dermal papillae alternate with the 
downward projections of the epidermis, the rete ridges. Together these structures 
markedly increase the area of contact between dermis and epidermis and increase 
the stability of the dermo-epidermal junction. The collagen fibre bundles in the 
papillary dermis are thin, poorly organised, and mainly consist of collagen type I and 
III (44). Elastic fibres found in the papillary dermis are thin and in a vertical orientation 
to the dermo-epidermal junction. In the papillary dermis of the finger tips, tactile 
corpuscles can be found which act as mechanoreceptors (1). 
The underlying reticular dermis shows collagen bundles which are thick and 
well organised. These bundles show a parallel orientation to the skin surface. The 
elastic fibres of the reticular dermis are thicker compared to the elastic fibres of the 
papillary dermis. The reticular dermis overlies the subcutaneous fat layer. The 
papillary and reticular dermis are separated by a vascular plexus, the rete 
subpapillare (45). 
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Figure 8: Haematoxylin and Eosin staining of normal human skin. Haematoxylin & Eosin staining 
of normal human skin. The dermis is divided into the papillary and reticular dermis. These two layers 
are separated by the rete subpapillare. Scale bar 45 µm. (44) 
 
 
Extracellular matrix 
 The main class of molecules in the extracellular matrix are collagens. 
Additionally, other macromolecules such as fibronectin, elastin, laminins and 
proteoglycans can be found. The different macromolecules of the extracellular matrix 
assemble into a network. The composition and architecture of this network 
contributes to the properties of the tissue (46). Components of the extracellular 
matrix are synthesised by dermal fibroblasts in response to diverse growth factors 
and cytokines. Metalloproteinases are involved in the degradation of these 
components (47). 
The different collagen types all share the same basic structure. Three 
polypeptide chains form a left-handed triple helix, which is held together by hydrogen 
and covalent bonds (48-49). In normal human skin, collagen type I is with ~90% the 
most abundant collagen type. Collagen type III has a content of ~10%. Collagen type 
V has a small content of only ~2% (50). 
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Fibroblasts 
The main cell type found in the dermis is the fibroblast. These mesenchymal 
cells can also be found in many other organs as they are the most prominent cell 
type in connective tissues. Independently of the organ in which they are located, they 
share their spindle-shaped morphology (Figure 9), but it has been shown that they 
differ in their gene-expression profile, depending on the anatomical location (51). The 
main function of fibroblasts is the synthesis and deposition of the different types of 
fibres and macromolecules that constitute the extracellular matrix. But they also have 
a crucial role in supporting growth and stratification of the epidermis and in wound 
healing. 
 
 
 
Figure 9: Human fibroblasts in culture. Morphology of human primary fibroblasts on cell culture 
plastic as seen in 
a) light microscopy and with 
b) immunofluorescence staining. The cells are positive for the human fibroblast marker CD90 (green). 
Nuclei are stained with Hoechst (blue). Scale bars 20 µm. 
 
 
Although fibroblasts are the dominant and essential cell type in the dermis, 
their population is highly heterogeneous, depending on the exact location within the 
dermis, but also within the body (45,52). Papillary fibroblasts show a higher 
proliferation rate and when cultured in monolayers reach a higher cell density 
because they are not completely contact inhibited (45,53). When seeded into a 
collagen type I hydrogel, reticular fibroblasts contract the hydrogel faster than 
papillary fibroblasts (54). Differences can also be observed regarding their production 
of matrix molecules. It was shown that papillary fibroblasts produce only low levels of 
versican. In contrast, reticular fibroblasts produce high levels of this protein (44-45). 
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Other differences between different types of fibroblasts can be seen regarding 
their capacity to support basement membrane formation. It was shown that 
myofibroblasts isolated from a wound site do not support keratinocyte differentiation 
and basement membrane deposition as well as fibroblasts isolated from an 
unwounded site do (55). Small quiescent fibroblasts, the fibrocytes, which do not 
show any obvious metabolic activity, can be found in mature connective tissue. 
Fibroclasts are fibroblasts with phagocytic activity (1,56). 
Fibroblasts are essential for the proliferation and differentiation of 
keratinocytes. One of the first factors identified to be secreted by fibroblasts and to 
regulate keratinocyte proliferation and differentiation was keratinocyte growth factor 1 
(KGF-1). This factor is exclusively produced by mesenchymal cells; however, only 
epithelial cells express the according receptor and therefore are able to respond to 
KGF-1 (57-58). KGF-1 overexpression leads to a certain hyperplasia of the 
epidermis, which might be a result of increased proliferation of basal keratinocytes 
and suppression of their terminal differentiation (59). Other factors that are secreted 
by fibroblasts and that regulate the biology of keratinocytes and are involved in 
wound healing include epidermal growth factor (EGF) (60), interleukin 6 (61), 
granulocyte colony-stimulating factor (GCSF) (62), and hepatocyte growth 
factor/scatter factor (HGF) (63). 
 
 
Basement membrane 
 The basement membrane separates the epithelial cells from the underlying 
connective tissue. It can not only be found in the skin but also in diverse organs such 
as in the digestive tract, lung, kidney and cornea. It is a multi-molecular sheet-like 
structure that consists of different glycoproteins and proteoglycans such as 
collagens, laminins, integrins, entactin, and dystroglycans (64). The formation and 
organisation of the basement membrane needs the interaction of both, basal 
keratinocytes and stromal fibroblasts (65-66). The basement membrane has several 
important roles: 1) It is essential for the adhesion of the epidermis to the dermis. 2) It 
is involved in the regulation of exchange of metabolic products between dermis and 
epidermis, and 3) it functions as a support for keratinocyte migration in wound 
healing (1). 
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 The basement membrane is composed of four layers (Figure 10), which were 
identified by electron microscopy. The uppermost layer is composed of the cell 
membranes of the basal keratinocytes, where the intracellular keratin filaments are 
anchored to hemidesmosomes. Below these cell membranes, the lamina lucida can 
be found, which is approximately 40 nm thick and consists of various 
macromolecules such as laminin 5. Anchoring filaments, composed of collagen type 
VII, reach from hemidesmosomes through the lamina lucida to the lamina densa, 
which is 50-70 nm thick and mainly composed of collagen type IV and laminin 5. The 
sub-basal lamina filamentous zone is mainly composed of anchoring fibrils (Figure 
10a) (67). 
Laminin 5 (also named laminin 332 according to its chains α3, β3, and γ2) can 
only be found in the basement membranes of stratified epithelia such as the skin and 
mucosa (64). It is essential for the anchoring of the epidermis to the dermis. 
 
 
 
Figure 10: Characteristics of the basement membrane. 
a) Schematic view of the organisation of the anchoring elements between the epidermis (E) and the 
dermis (D). 
b) Haematoxylin and Eosin staining of human skin. (E) Epidermis, (D) dermis. 
c) Electron micrograph of the basement membrane, showing lamina densa (LD), lamina lucida (LL), 
hemidesmosomes (HD), anchoring fibrils (AF) and the nucleus of a basal keratinocyte (N). 
d) High magnification of the region shown in (c) encircled. Additionally to the components observed in 
c), a subbasal dense plate (sbdp) can be seen. The hemidesmosome can be structured into an inner 
plaque (IP) and an outer plaque (OP) in contact with the plasma membrane (PM). 
d) Schematic representation of the architecture of the epidermal anchorage. Scale bars 0.1µm. 
Modified from (68-70) 
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Development of the dermis 
 During the first six weeks of gestation of a human embryo, the embryo is 
covered by the single-layered periderm and thereafter by a two-layered epidermis. 
During this time, the dermis has not yet developed. Instead of the dermis, a 
subepidermal cellular layer is found and collagen type IV and laminin 5 can be 
detected (37-38). Already at eight weeks, the development of the vasculature starts. 
During weeks nine and ten of gestation, the basement membrane develops with cell 
adhesion and expression of integrin α6 and integrin β4. Also during this time, the 
extracellular matrix is deposited. Merkel cells that first can be found in the epidermis 
are then also detectable in the dermis. (38) 
 
 
3.1.3 Skin appendages 
 
Hair follicles 
The development of hair follicles (Figure 11) starts at the end of the first 
trimester of pregnancy in humans. They are mainly formed by ectodermal epidermal 
cells and reach deep into the dermis (3). For their formation in the fetus, fibroblasts 
play a significant role and the crosstalk between the fibroblasts and keratinocytes is 
essential (71-72). The formation of a hair follicle starts with mesenchymal cells 
signalling to the overlying epidermal cells to form small epidermal invaginations into 
the dermis, the so called hair placodes (left part of Figure 11) (73). The dermal 
papilla cells then signal to the cells in the hair placode to grow downwards, with the 
matrix cells at its leading front, and to form the hair follicle. Further crosstalk between 
the mesenchyme and epithelium leads to the maturation of the hair follicle (72,74). 
The hair is surrounded by seven concentric layers of terminally differentiated 
matrix cells. The outer root sheath is composed of several layers. The outermost 
layer is the one showing the least differentiation. The outer root sheath always stays 
in contact with the basement membrane. The inner root sheath consists of three cell 
layers (72,75). The mature hair follicle can be divided into several segments; these 
differ in their structure and also in their behaviour during the hair cycle. The 
uppermost part of the hair is the intraepidermal part. From there, the infundibulum 
reaches down to the opening of the sebaceous gland. The isthmus extends from the 
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sebaceous gland down to the bulge, which is where the arrector pili muscle attaches. 
The structure between the bulge and the hair bulb is called lower follicle. The hair 
bulb is responsible for the growth of the hair and contains melanocytes. The bulb 
forms a cavity which contains stromal cells and is highly vascularised and innervated. 
This mesenchymal cavity is referred to as the dermal papilla. (1,76) 
The upper parts of the hair are differentiated and do not change markedly 
during the hair cycle. In contrast, the structures of the lower parts vary depending on 
the state of the cycle. The hair grows in the anagen phase by proliferating 
keratinocytes located above the dermal papilla. In the regression phase, the catagen, 
the lower parts of the hair follicle undergo apoptosis (Figure 11) (77). During the 
telogen phase (Figure 11), in humans the hair follicle rests up to several months, 
before the anagen phases starts again upon activation of the hair follicle stem cells 
(75). The bulge of a hair follicle is an important stem cell niche of the skin (75,78). In 
the anagen phase of the hair follicle, stem cells migrate off the bulge, proliferate and 
differentiate into the cell lineages of the hair follicle, which can be distinguished by 
the expression patterns of different keratins, which are characteristic for the different 
concentric layers of the hair follicle (79-80). In addition to their function in the normal 
hair cycle, keratinocyte stem cells of the bulge are involved in the process of skin 
wound healing. Upon wounding of the surrounding epidermis, they migrate out of the 
bulge and contribute to the closure of the epidermis (81-84). 
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Figure 11: Schematic view of the hair cycle in humans. The hair cycle starts with the regression 
phase, the catagen. During the catagen, the lower hair undergoes apoptosis and regresses. At the 
end of this phase, the dermal papilla can be found directly under the bulge region. After the resting 
phase, the telogen, the stem cells of the hair are activated and growth of the hair starts again. (75) 
 
 
Sebaceous glands 
 Sebaceous glands (Figure 11) are mainly associated with hair follicles, 
therefore they can be found in all areas of the body, except in hairless skin. They are 
located between the skin surface and the arrector pili muscle. Higher numbers of 
sebaceous glands, and also larger gland sizes, can be found in regions exhibiting 
small vellus hairs, which is the case in facial skin (3). 
Progenitor cells of the sebaceous gland constantly proliferate and give rise to 
cells that differentiate into terminally differentiated sebocytes. These cells produce 
lipids and sebum. For the secretion, the sebocytes disintegrate and the release their 
content into the hair canal. The oils and sebum function as protection for the hair 
against bacterial infections and as lubrication. Hormones play an important role in the 
control of sebaceous gland secretion. (1,3) 
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Sweat glands 
 In humans, two types of sweat glands (Figure 12) can be distinguished, 
namely eccrine sweat glands and apocrine sweat glands. Both types consist of a 
secretory coil and an excretory duct. Eccrine sweat glands are the dominant type in 
humans and can be found almost all over the body. They have a major role in 
thermoregulation by producing an odourless, hypotonic clear fluid (85). Their highest 
density can be observed over the palms, soles, axillae and forehead, with up to 300 
sweat glands per square centimetre. The secretory coil reaches deep into the dermis 
and consists of one cell layer composed of myoepithelial cells and dark and clear 
secretory cells. The excretory duct is composed of two cell layers, the peripheral cell 
layer and the inner cell layer (1). 
 Apocrine sweat glands are less abundant in humans, they can be found in the 
axillae, anogenital region and nipples. They produce an odourless, milky fluid, which 
after puberty produces a viscous secretion that is acted on by bacteria to produce a 
characteristic odour (86). 
 It has been shown that eccrine sweat gland cells can contribute to epidermal 
wound healing by stem cells that migrate out of the sweat gland, similar to stem cells 
found in the hair follicle bulge (87-89). 
 
 
                  
Figure 12: Schematic view of the two types of sweat glands in humans. 
a) Eccrine sweat gland. 
b) Apocrine sweat gland. Modified from (90) 
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3.2 Skin injury and wound healing 
 
3.2.1 Thermal injuries 
 
Extensive skin loss can result from many reasons such as acute soft tissue 
trauma, genetic disorders, chronic wounds, skin diseases, or tumours. Thermal 
trauma, such as scalds and burns, is one of the most common causes for major skin 
loss. It is estimated that in Switzerland annually 70’000 burn accidents occur. 1000 of 
these victims need to be hospitalised, and 200 are treated in a specialised burn care 
centre. One third of these patients are children (91). Hospitalisation is needed when 
the burn area exceeds more than 10% of the total body surface area in adults, and 
5% of the total body surface area of children (92). 
Burn injuries are categorised into four classes according to the depth of the 
wound (Table 3). Using the self-healing capacity of the skin, skin wounds of the 
classes I-III can regenerate. In such wounds, keratinocytes from the borders of the 
wound but also from hair follicles and sweat glands in the remaining dermis change 
into a proliferating migratory cell type and contribute to the healing and re-
epithelialisation process (81,84,88,93). Deep partial-thickness skin wounds show a 
greater dermal damage, which leads to slower healing because fewer skin 
appendages can contribute to the healing process. Additionally, scarring is severe in 
this class of injury compared with superficial partial-thickness wounds. After a class 
IV injury, all the components of the skin that could contribute to the regeneration are 
completely destroyed, leaving a wound that only can heal from the wound edges and 
by contraction. This leads to an unsatisfactory outcome with regard to function and 
cosmetics. In these cases, the wound size is critical, as full-thickness wounds with a 
diameter of more that 1 cm would heal with extensive scar formation (94). 
 
 
INTRODUCTION 
26 
Table 3: Skin defects. Overview on the categories of skin defects. Modified from (92) 
 
Skin defect class Depth of injury Clinical description 
Class I Epidermal No blisters, dry, red, painful 
Class II a Superficial partial-thickness Blisters, moist, red, painful 
Class II b Superficial partial-thickness Blisters, less moist, dotted pink, painful 
Class III Deep partial-thickness Dry, white, painless 
Class IV Full-thickness Charred, painless 
 
 
3.2.2 Wound healing 
 
The process of wound healing is very similar all over the human body; the 
process differs little whether it is a myocardial infarction, an injured lung or a skin 
wound, and it consists of three overlapping phases, namely 1) inflammation, 2) new 
tissue formation and 3) remodelling (Figure 13).  
As a first step of the inflammation-phase of skin wound healing and 
immediately after injury, platelets aggregate to form a haemostatic plug and blood 
coagulates, forming together a clot that serves as a temporary barrier to the wounded 
area and as a provisional repair matrix. This matrix is mainly made of cross-linked 
fibrin fibres, derived from thrombin cleavage of fibrinogen, and smaller amounts of 
plasma fibronectin, vitronectin and thrombospondin (95). The clot also serves as a 
substrate for cell adhesion and migration. Activated platelets degranulate and release 
growth factors and adhesive proteins, leading to an inflammatory response and cell 
migration into the wound area. Neutrophiles arrive at the wound site within minutes; 
they react to changes in the surface of the endothelial cells lining the blood vessels at 
the wound site. Monocytes arrive 2-3 days after injury and differentiate into 
macrophages and together with the neutrophiles they clean the wound by 
phagocytosing and solubilising cell- and matrix debris and pathogenic organisms. 
The neutrophiles are also involved in producing pro-inflammatory cytokines that are 
used as very early signals to activate local fibroblasts and keratinocytes (Figure 13a). 
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Figure 13: Schematic view of the three classical wound healing stages. 
a) Characteristic for wounds in the first stage, the inflammation phase, is the formation of a fibrin clot 
and the presence of bacteria, platelets and neutrophiles in the wound area. 
b) During the phase of new tissue formation an eschar has formed, most cells of the previous phase 
are not anymore present and blood vessels grow into the area. Under the eschar, keratinocytes 
migrate to close the wound. 
c) During the third phase, tissue remodelling occurs. Fibroblasts deposit collagen in dense parallel 
bundles (violet lines) and the wound contracts. The reconstituted scar tissue does not contain any skin 
appendages. (96) 
 
 
In the second phase, during days 2-10 after wounding, haematopoietic as well 
as mesenchymal cells from the circulation and the surrounding tissues are attracted 
to the wound site. Fibroblasts and capillaries invade the temporary fibrin matrix to 
replace it with a contractile granulation tissue, which is mainly composed of collagen 
type III. This new tissue has a pink granular appearance that results from numerous 
capillaries growing into the provisional matrix. Usually now the wound margins are 
concentrically contracted, with the help of fibroblasts that had differentiated into 
contractile myofibroblasts. Keratinocytes from the wound margins migrate to close 
the wound area. Keratinocytes from hair follicles and sweat glands migrate off these 
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skin appendages to participate in wound closure. First, the keratinocytes form a 
monolayer, then a new basal lamina is formed and the cells stratify. In the wound 
area, an oxygen gradient is created by the diffusion of oxygen from the blood vessels 
at the wound edges. Fibroblasts at the wound borders produce collagen type III, a 
process supported by the high-oxygen concentration in this area. The hypoxic 
environment in the centre of the wound is essential for the macrophages, which 
release cytokines that stimulate chemotaxis and mitosis (Figure 13b). 
2-3 weeks after injury, the last phase of the wound healing process starts, and 
most of the processes of the first two phases are terminated. After wound closure, 
the cells in the granulation tissue undergo apoptosis and during the following months, 
the collagen-rich scar tissue is re-modelled. During 6-12 months after injury, matrix 
metalloproteases secreted by fibroblasts, macrophages and endothelial cells, 
transform the matrix from a matrix mainly composed of collagen type III to one that is 
largely composed of collagen type I. This re-modelling phase can last for more than 
one year (Figure 13c). (96-98) Figure 14 shows an overview of the time course of 
these wound healing processes in mammals. 
 
 
 
Figure 14: Time course of the wound healing process in mammals. The x-axis in this scheme 
represents the time, whereas the y-axis represents the strength of the response for each process. The 
colours highlight the individual overlapping processes during the three main wound healing phases 
inflammation, new tissue formation and tissue remodelling. (99) 
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3.2.3 Scarring 
 
Ideally, wound repair would result in a tissue showing the same structure, 
function and aesthetics as the uninjured skin. But in most cases, the outcome of 
wound healing in mammals is fibrotic scar tissue. The consequences of this scar 
repair often include loss of function, movement restriction and disfigurement (Figure 
15) (38,100). Scarring results from excessive accumulation of unorganised 
extracellular matrix, mainly collagen, deposited by myofibroblasts which, under the 
influence of TGFβs 1 and 2, show characteristics of smooth muscle cells (101). In 
intact non-wounded dermis, the collagen shows a mechanically efficient basket-
weave meshwork. In contrast, the collagen in scar tissue is deposited in dense 
parallel bundles (95). Additionally, modifications in the vascularisation can often be 
found together with changes in cell proliferation of the cells in the originally injured 
area. If the injury is deep, no remnants of hair follicles and sweat glands are left; 
hence, the repaired skin will fail to regenerate those. Time is a critical component in 
wound healing and scarring. The faster a wound heals, the better the outcome is with 
respect to scar formation (38).  
 However, although today the treatment of skin defects includes scar 
prevention, the revision of scars remains a major challenge of reconstructive surgery 
(100). 
 
 
 
Figure 15: Disfiguring scars in three burn patients. (a, c, e) lateral view, (b, d, f) frontal view. 
(a, b) 16 year old adolescent. 
(c, d) 12 year old patient. 
(e, f) 12 year old patient. Modified from (100) 
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Fetal wound healing 
Complete regeneration is found in lower vertebrates (e.g. salamanders) and 
invertebrates (102). Scar less wound healing can only be found in early mammalian 
embryos (103). In mammals, the fetal dermis reacts to tissue damage with 
generating a non-disrupted collagen matrix that is identical to the unwounded dermis. 
However, this scar less repair mechanism is only observable until a certain transition 
time point, after which also in fetuses skin injury results in scar formation. This 
transition point from scar less wound healing to scarring is found approximately in 
week 24 of gestation in humans. During the period a mammal fetus shows scar free 
wound healing, the fetus has an immature endocrine system as well as an immature 
immune system and the cells of the fetus exist in a hypoxic environment (104). 
During this phase, the fetus can restore normal tissue architecture and reconstitute 
even the appendages. 
The mechanisms why wounds can heal without any scar formation until a 
certain transition point still are not completely understood. Many studies investigated 
the differences between human fetal and adult skin. Differences detected include a 
higher ratio of collagen type III to collagen type I in fetal skin, a higher level of 
glycosaminoglycans in the extracellular matrix (ECM) in fetal skin, and the absence 
of the ECM component elastin in fetal dermis (42). Amongst the many differences 
that were found in fetal wound healing compared to wound healing in adults are the 
missing conversion of fibroblasts into myofibroblasts and the absence of a significant 
angiogenic response (95,105). 
 
 
3.2.4 Current treatment of burn injuries 
 
 Any skin injury that exceeds 4 cm2 in diameter will not show good 
spontaneous healing. In these cases a skin graft can significantly improve the 
outcome (106). The today’s gold standard of treating severe and large skin defects is 
the early debridement of the destroyed tissue and the transplantation of autologous 
split-thickness skin grafts harvested from an unaffected body area, the so called 
donor site (107-112). 
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 Split-thickness skin is consists of the epidermis and only a thin layer of dermis 
(Figure 16a). Split-thickness skin is harvested from the donor site with the help of a 
dermatome and transplanted to the wound site, where the capillaries of the split-
thickness skin graft will anastomose with the capillary network of the wound site. The 
donor site will heal properly within a week, as a sufficient number of keratinocytes 
remains in the skin appendages located in the dermis, hence the donor site can be 
re-used three to four times to harvest split-thickness skin (110). 
 Transplantation of autologous full-thickness skin grafts (Figure 16b) can only 
be performed in patients with injured areas of less than 2% of the total body surface 
area (113). With full-thickness skin grafts the contraction at the wound site will be 
minimal and there will be almost no scar. However, the donor site will take longer to 
heal. An additional disadvantage of full-thickness skin grafts is that donor and 
recipient sites should match well because of potential skin mismatches due to the 
very diverse skin specialisations seen over the total body area (38). 
 A major drawback of the use of split-thickness skin grafts may be that donor 
sites are extremely limited when large areas of the body (e.g. 80% TBSA) are 
severely injured, or the physical condition of the patient will not allow the harvesting 
of skin. When using split-thickness skin grafts, the area that is available to cover the 
defect can be enlarged by meshing the graft. However, meshing of the split-thickness 
skin leads to a suboptimal deprived cosmetic result and poor functional outcome, due 
to the lack of dermal and epidermal components in the gaps of the meshed graft (94). 
Skin expansion in vivo, i.e. in the patient itself, can be reached by subcutaneous 
insertion of inflatable devices (expanders) (114), which can be enlarged stepwise, 
resulting in expansion of the overlying skin by cell proliferation. The advantage of 
such an expanded skin is that it is composed of all skin layers and that it shows the 
characteristics of the donor site (38,115). 
 The best surgical results can be obtained when the split-thickness skin graft is 
transplanted in combination with a dermal template (116), such as Integra Dermal 
Regeneration Template® (100,107,113,117-119) or Matriderm® (116,120-124). It has 
been shown that the use of such off the shelf, acellular templates can improve wound 
healing and reduce scar contraction (125-126). In the following, I will consider three 
different templates for skin reconstruction in more detail. 
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Figure 16: Split-thickness and full-thickness skin. Schematic representation of the composition of 
a) split-thickness skin and 
b) full-thickness skin. 
 
 
Integra Dermal Regeneration Template 
 The product Integra Dermal Regeneration Template® 2 mm (Integra, Integra 
Life Science Corp., Plainsboro, NJ, USA) (Figure 17a) is composed of two different 
layers: The dermal layer is composed of bovine cross-linked tendon collagen and 
glycosaminoglycans from shark cartilage. The second layer consists of a temporary 
silicone sheet (94). It is applied in a two-step procedure: after initial transplantation of 
Integra, cells from the patient will grow into the dermal layer and will permanently 
colonise it to form a neo-dermis. In a second surgery 15-20 days after the initial 
transplantation of Integra, the silicone sheet will be peeled off, and the now 
vascularised neo-dermis will be covered with an autologous split-thickness skin graft 
(127). As it is an acellular product, it can be applied off-the-shelf and has no 
limitations in availability. The indication for the use of Integra is post-excisional 
treatment of deep-partial thickness or full-thickness skin defects, but it can also be 
applied for scar revision and other reconstructive surgeries at almost all body sites 
(128). The results obtained with Integra show regeneration of near normal skin with 
only minimal scarring. Disadvantages are the long repopulation time and the 
necessity of two successive operations (100,129-130). 
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Matriderm 
 The product Matriderm® (Matriderm, Dr. Suwelack Skin and HealthCare AG, 
Billerbeck, Germany) (Figure 17b) is a matrix of bovine non-cross-linked lyophilised 
dermis. The surface is coated with α-elastin hydrolysate. Matriderm is intended to 
substitute for the dermis and it can be applied simultaneously with split-thickness skin 
in a single surgical intervention (131). It is an off-the-shelf product that therefore has 
no limitations in availability and serves as a permanent dermal substitute. However, 
since it is rapidly degraded, it is not clear whether Matriderm has a true advantage in 
applications other than hand surgery (121,132). 
 
 
Apligraf 
 The product Apligraf® (Apligraf, Organogenesis, Inc., Canton, MA, USA) 
(Figure 17c) is, in contrast to Integra and Matriderm, a cellular product. It is based on 
a bovine collagen type I gel matrix, combined with allogenic fibroblasts and 
keratinocytes form neonatal foreskin (127). As it is a living product, it has a shelf-life 
of only five days at room temperature, and the allogenic cells contained in Apligraf 
make it only a temporary wound dressing. These allogenic cells are efficient for pain 
relief and support for wound healing, but it has been shown that they do not survive 
in the patient longer than one to two months (133-134). Apligraf is licensed for use in 
the treatment of venous leg and diabetic foot ulcers, but there are no reports of large 
clinical trials for its use in burns treatment (94). 
 
 
      
Figure 17: Examples for commercially available products for skin reconstruction. 
a) Integra Dermal Regeneration Template. 
b) Matriderm. 
 c) Apligraf. (135-137) 
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3.3 Bio-engineering of skin 
 
3.3.1 Definition of tissue engineering 
 
An article published in 1992 by Robert M. Nerem describes the working 
definition of the term “tissue engineering” as follows: 
 
“Tissue engineering is the application of the 
principles and methods of engineering and the life 
sciences toward the fundamental understanding of 
structure/function relationships in normal and 
pathological mammalian tissues and the 
development of biological substitutes to restore, 
maintain or improve functions.” (138) 
 
This definition is today, 20 years later, still valid. Tissue engineering has the 
ultimate goal of creating living replacements for tissues and organs of the body (139). 
The field of tissue engineering has developed, and researchers all over the world are 
working on engineering different tissues and organs such as skin, nerves, heart 
valves (140), and bone (141), to supply the constantly growing need for tissue and 
organ transplantations (142). Independently of the tissue or organ that is to be 
engineered, two major points have to be considered. Firstly, there is the need for a 
cell source that can provide cells capable of differentiating and/or forming the desired 
tissue or organ. Secondly, for these cells an appropriate growth and differentiation 
factors have to be used, and an appropriate extracellular matrix has to be provided. 
This ECM ideally exhibits both, excellent biological properties and convenient 
handling by the surgeon. 
For tissue engineering, the understanding of the physiology of the tissue or 
organ to be reconstructed is fundamental, but at the same time the exact needs for 
clinical application have to be specified in detail. Therefore the collaboration between 
different disciplines such as basic research, translational research and clinicians is 
essential. 
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3.3.2 Historic perspectives 
 
 A first essential step towards tissue engineering of skin was achieved in 1975, 
when successfully cultured keratinocytes were reported by Rheinwald and Green. 
They were able to generate small sheets consisting of about two to three layers of 
human keratinocytes. These keratinocytes were grown on a feeder layer of lethally 
irradiated 3T3 murine fibroblasts, and with this Rheinwald and Green were the first to 
describe the complex relationship between mesenchymal fibroblasts and epithelial 
keratinocytes (143). Based on the success of these researchers, cultured epidermal 
autografts were tested worldwide at many different burn centres. A major 
shortcoming of this method was the very variable take of the cultured epidermal 
autografts (144-151). Only some years after the first successful cultivation of 
keratinocytes a dermo-epidermal skin substitute was developed in 1981 and later 
refined as the above described product Apligraf, containing allogenic fibroblasts and 
keratinocytes (152). Also in 1981, Burke and Yannas reported the development of an 
artificial skin based on an acellular collagen-glycosaminoglycan matrix. This product, 
since 1996 commercially available in the USA, and now known as Integra, today still 
is very important for the treatment of severe skin defects in combination with split-
thickness skin. In 1995, cultured autologous fibroblasts and keratinocytes were 
transplanted onto Integra in burn patients (153). However, it appeared that this did 
not lead to any success as neither case reports of treated patients, nor follow-up 
reports or any results of clinical trials of these experiments were published. 
 
 
3.3.3 The bio-engineering of skin: “Skingineering” 
 
The necessity for bio-engineered skin 
The coverage of large skin wounds with autologous split-thickness skin is the 
current gold standard. However, in severely injured patients, if the defect exceeds 
50-60% of the total body surface area, the availability of donor sites is very limited, 
and these donor sites would add to the total injured area which represents and 
additional risk for these patients (154). Patients in which even meshing of the split-
thickness skin grafts does not allow to cover all skin areas, wound dressings or 
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cadaver skin are used as temporary coverage to prevent fluid loss and microbial 
contaminations, and delayed serial grafting of split-thickness skin is performed (155). 
Such wounds which cannot heal over a long period of time represent a high risk for 
complications and will not result with a satisfactory outcome (156). Additionally, 
harvesting of split-thickness skin can result in scarring, in particular in children who 
frequently may suffer from disabling and disfiguring hypertrophic scars, or keloid 
formation (157). Alternative treatment methods without the need for large donor sites 
for harvesting split-thickness skin may considerably improve the perspectives of 
patients with severe skin defects.  
Chronic wounds associated with old age and diabetes are increasing in the 
developed world. These wounds significantly increase health care costs and are a 
major problem for the affected patients. In these patients, tissue engineered skin 
substitutes may significantly support wound healing (158-159). 
Other fields with increasing potential for the use of bio-engineered skin are 
scar revisions, reconstructive surgery, correction of pigmentation defects such as 
vitiligo, and congenital nevi (160). 
 
 
Materials for bio-engineering of skin 
Tissue engineering depends on the use of an appropriate material. The 
material serves as a substitute for the extracellular matrix, in which cells can be 
integrated in a three-dimensional way. Additionally, factors can be included into it 
which serve as stimuli to direct the growth and differentiation of the incorporated cells 
(161). The ideal material for skin bio-engineering must not induce an immune 
response, excessive inflammation, or toxic reaction. If possible there should be no or 
only a very low risk for disease transmission for materials composed of animal 
derived components. Furthermore, it should degrade over time but support the tissue 
reconstruction and show similar properties as the normal skin (162). FDA-approved 
polymer materials include animal derived substances such as bovine collagen but 
also synthetic materials such as poly(lactic-co-glycolic acid). They can either be solid, 
but alternatively hydrogels, composed of hydrophilic polymer chains, can be used 
showing good characteristics. Also the materials for hydrogels can either be synthetic 
or natural (163). The choice of material that is used highly depends on the tissue of 
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interest and its application. In the following, a natural as well as a synthetic polymer 
for skin tissue engineering will be discussed exemplarily in more detail. 
 
Natural polymer – Collagens: 
For bio-engineering of human skin, one of the most important scaffold 
materials for hydrogels is the naturally derived collagen type I. In mammals, collagen 
is the main protein of the extracellular matrix and contributes with 25% to the total 
protein mass (19,48). Collagen itself can create stable fibres, but the mechanical 
properties and stability of the fibres can additionally be enhanced by cross-linking 
with chemicals (164), physical treatments such as UV irradiation (165), or, by 
blending with other polymers (132). The requirements for a collagen type I hydrogel 
used in skin tissue engineering are divers. For example, when cells should be 
integrated into the collagen hydrogel, the hydrogel must polymerize without 
damaging the cells and must allow appropriate diffusion of nutrients. Additionally, it 
should provide enough mechanical integrity for that it can be handled in the 
laboratory as well as in the operation theatre (142). Collagen type I hydrogels are not 
only used for skin tissue engineering (21,88-89), they also have been used for tissue 
engineering of skeletal muscle (166), adipose tissue (167), and blood vessels (168). 
As collagen is an animal derived material, it carries the risk of disease transmission 
(169). However, for the production of skin substitutes under GMP (Good 
Manufacturing Practice) guidelines for clinical application, collagen type I is available 
that fulfils all regulatory and quality regulations, i.e. collagen type I with certificate of 
origin, certificate of analysis, and certificates for testing for sterility, endotoxines and 
mycoplasma. Therefore the actual risk for disease transmission from animal to 
human can be minimised. 
 
Synthetic polymer – PLGA: 
Many biodegradable and biocompatible synthetic polymers have been studied 
to serve as material for tissue engineering. Poly(lactic-co-glycolic acid) (PLGA) is 
widely used for tissue engineering (170), as this material is FDA approved and not 
expensive. PLGA can be processed easily and the microstructure and morphology 
can be controlled. The mechanical strength as well as the degradation time of PLGA 
can be adjusted to different needs by changing the ratio of lactide and glycolide 
(171). As lactide is more hydrophobic than glycolide, PLGA polymers composed of 
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more lactide are less hydrophilic, therefore absorb less water and degrade slower 
compared to PLGA polymers with higher glycolide contents (172). In vivo, PLGA 
polymers will degrade into lactic acid and glycolic acid. Lactic acid is metabolised and 
eliminated from the body as carbon dioxide and water. Glycolic acid is either directly 
excreted in the kidneys or it is metabolised similar to lactic acid and eliminated from 
the body as carbon dioxide and water (173). With electro-spinning, ultra-fine PLGA 
fibres can be formed using a high-voltage electrostatic field which charges a 
suspended drop of PLGA. With this technique, scaffolds can be generated that have 
a high surface area-to-volume ratio and provide a good substrate for cell attachment 
(174). Additionally, PLGA sheets can be produced to incorporate them into other 
matrices to give additional support. Scaffolds are usually no ideal substrate for cells, 
thus they mostly have to be combined with ECM components, such as collagens, 
fibrin, or hyaluronic acid. 
 
 
Quality criteria for bio-engineered skin substitutes 
 The major requirements that need to be fulfilled by all bio-engineered skin 
substitutes, whether they are dermal, epidermal, or, dermo-epidermal skin 
substitutes, are: safety for the patient, clinical effectiveness and convenience in 
handling and application (124). A transplanted skin substitute needs to adhere to the 
wound bed and be incorporated and supported by the vasculature. The critical 
thickness for sufficient ingrowths of blood vessels that a skin graft cannot exceed is 1 
mm (175). When using dermal substitutes, sufficient vascularisation can often only 
be achieved with a two-step procedure to provide sufficient time for the needed 
vascularisation, though this leads to an additional stress for the patient. Moreover, 
the skin substitute has to be accepted by the patient’s immune system, and it has to 
serve as a permanent graft (160). Additionally, an engineered skin substitute should 
exhibit similar properties as normal skin with regard to elasticity and pigmentation, 
and it should not contract upon transplantation. 
The bio-engineered products for skin reconstruction that are currently 
available do not yet fulfil all the above mentioned requirements to a completely 
satisfactory extent and therefore there is still a high necessity for novel, more 
functional dermo-epidermal skin substitutes (94,113).  
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Plastic compression of collagen hydrogels 
 Collagen hydrogels have been shown to have high potential for tissue 
engineering purposes (21,88-89,166-168). To generate large, more stable collagen 
hydrogels for skin tissue engineering, Braziulis et al. (176) modified a method 
previously published by Brown et al. (177) to create 7x7 cm compressed collagen 
hydrogels.  Plastic compression of a collagen hydrogel in a compression chamber 
(Figure 18) densifies the collagen fibres. This leads to reduced gel contraction and 
degradation and therefore to a more stable, functional collagen hydrogel. 
 
 
 
Figure 18: Plastic compression of collagen hydrogels (7x7 cm). 
a) Schematic drawing of the compression chamber. 
b) Picture of the assembled compression chamber. (I) perforated base plate, (II) casting frame, (III) 
compression stamp, (IV) weights. 
c) Large square 7x7 cm compressed collagen hydrogel. (176) 
 
 
Novel skin grafts developed by the Tissue Biology Research Unit 
Phase I clinical trials are currently being prepared with two skin substitutes 
developed and produced by the TBRU. 
Firstly, denovoDerm (Figure 19a) is a tissue-engineered, autologous dermal 
substitute. It consists of a compressed collagen type I hydrogel with incorporated 
autologous dermal fibroblasts. After a short cultivation phase in vitro of about 6-8 
days, this dermal substitute will be transplanted onto the wound bed. As denovoDerm 
has no epidermal compartment, autologous split-thickness skin will be used to cover 
this dermal substitute at the same surgical intervention. On the patient, this dermal 
substitute will develop into a fully functional dermis greatly supporting the split-
a cb 
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thickness skin that it is tightly connected to. In phase I clinical trials, it will be applied 
on acute as well as on elective patients with not more than 25% TBSA affected. 
Secondly, denovoSkin (Figure 19b) is a tissue-engineered, autologous dermo-
epidermal skin substitute. It consists of a compressed collagen type I hydrogel with 
incorporated autologous dermal fibroblasts and autologous epidermal keratinocytes 
seeded on top of this hydrogel. This dermo-epidermal skin substitute will be 
transplanted after a cultivation phase of 18-21 days in vitro. It will be applied directly 
onto the wound bed. As it also has an epidermal compartment, no additional 
coverage of this skin substitute with split-thickness skin will be needed. On the 
patient, this dermo-epidermal skin substitute will develop into a functional skin 
analogue. For this product, there are no limitations for the patient’s TBSA affected, as 
it is independent of split-thickness skin. (178) 
 
 
 
            
Figure 19: denovoDerm and denovoSkin. 
a) The dermal graft denovoDerm will be applied directly onto the wound bed and covered with 
autologous split-thickness skin. 
b) The dermo-epidermal graft denovoSkin will be applied directly onto the wound bed and requires not 
further covering with split-thickness skin. 
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3.4 Outline of this dissertation 
 
 In the following, a short background and the experimental outline of each of 
the publications included in this dissertation is presented. 
 
 
3.4.1 Publication I 
 
Collagen hydrogels strengthened by biodegradable meshes are a basis for dermo-
epidermal skin grafts intended to reconstitute human skin in a one-step surgical 
intervention: 
 Collagen hydrogels are widely used for tissue engineering purposes. Also at 
the TBRU, collagen type I hydrogels are used for the generation of most skin 
substitutes. However, collagen hydrogels tend to be fragile and handling is often 
difficult. Therefore we aimed in generating dermo-epidermal skin substitutes based 
on collagen type I hydrogels with incorporated biodegradable scaffolds. The scaffolds 
should stabilise the hydrogels for better handling characteristics and should be fully 
biodegradable and biocompatible especially with regard to epidermal growth and 
stratification. 
 Therefore we generated dermo-epidermal skin substitutes with different 
incorporated biodegradable scaffolds. The skin substitutes were analysed in vitro as 
well as in vivo, with special focus on epidermal stratification (Figure 20). 
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Figure 20: Experimental outline of publication I. Schematic overview on the experimental design of 
the manuscript entitled: Collagen hydrogels strengthened by biodegradable meshes are a basis for 
dermo-epidermal skin grafts intended to reconstitute human skin in a one-step surgical intervention. 
 
 
3.4.2 Publication II 
 
Human amniotic fluid derived cells can competently substitute dermal fibroblasts in a 
tissue engineered dermo-epidermal skin analogue: 
 Today, fetal surgery for spina bifida is performed at a few centres worldwide 
and also at the University Children’s Hospital Zurich in Switzerland. The skin defects 
resulting from spina bifida operation often are huge, compared to the small size of 
the fetus. Closure of these skin defects is often difficult, and in these cases fetal skin 
tissue engineering might help. We therefore raised the question whether we can 
engineer a fetal skin from cells contained in the amniotic fluid. This would be very 
appealing, as the amniotic fluid represents an easily accessible cell source not only 
after birth, but also already during pregnancy. In a first step towards engineered fetal 
skin, we wanted to evaluate whether human amniotic fluid derived cells (amniocytes) 
can take over the function of dermal fibroblasts, in particular with regard to supporting 
epidermal growth and stratification (Figure 21). 
To address this question, we used our procedure to generate dermo-
epidermal skin analogues based on a collagen type I hydrogel. From a human skin 
biopsy, we isolated human dermal fibroblasts and human epidermal keratinocytes. 
These cells we used to generate a dermo-epidermal skin substitute with incorporated 
fibroblasts and keratinocytes seeded on top of these hydrogels. The skin substitutes 
INTRODUCTION 
 43 
were transplanted onto the back of immuno-incompetent rats and analysed three 
weeks thereafter. As control, we generated skin substitutes with an acellular dermal 
compartment. Human amniocytes were isolated from samples of human amniotic 
fluid. These cells were then, instead of the usually used fibroblasts, incorporated into 
collagen hydrogels. As epidermal layer, the usually used epidermal keratinocytes 
were used. Also these grafts were transplanted onto immuno-incompetent rats and 
analysed after three weeks. All types of grafts were analysed macroscopically, 
histologically and with immunofluorescence stainings. 
 
 
 
Figure 21: Experimental outline of publication II. Schematic overview on the experimental design 
of the manuscript entitled: Human amniotic fluid derived cells can competently substitute dermal 
fibroblast in a tissue engineered dermo-epidermal skin analog. Scheme of amniocentesis modified 
from (179).  
 
 
3.4.3 Publication III 
 
A new model for preclinical testing of dermal substitutes for human skin 
reconstruction: 
The treatment of severe skin defects such as burns and congenital giant nevi 
often requires skin reconstruction. The today’s gold standard in such cases is the 
transplantation of autologous split-thickness, either directly onto the wound bed, or it 
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can be transplanted onto a dermal substitute such as Integra or Matriderm. The 
development of such dermal substitutes requires intensive preclinical testing for its 
biological behaviour and compatibility with split-thickness skin. As human split-
thickness skin is very limited for research purpose, we aimed in generating a model 
to test newly designed dermal substitutes in a humanized animal system, without the 
need for human split-thickness skin. 
We combined different dermal substitutes with different human coverage 
grafts and transplanted them onto the back of immuno-incompetent rats (Figure 22). 
Grafts were analysed 21 days thereafter. As gold standard we used Matriderm and 
human split-thickness skin. This we compared to an engineered human coverage 
graft. To generate human engineered grafts, we isolated dermal fibroblasts and 
epidermal keratinocytes from a human skin biopsy. We incorporated the fibroblasts 
into a collagen type I hydrogel, and seeded keratinocytes on top of these gels. We 
transplanted the split-thickness skin, consisting of the epidermis and some parts of 
the dermis, directly onto the fascia, on Matriderm, and onto an acellular collagen type 
I hydrogel. The same three groups we used for neonatal rat epidermis, which only 
consists of about 1 layer of keratinocytes, and no dermal components. The human 
engineered grafts, consisting of dermal and epidermal compartments, we 
transplanted as well directly onto the fascia, onto Matriderm and on the acellular 
collagen hydrogel. All combinations of grafts were analysed three weeks post 
transplantation macroscopically, histologically and with immunofluorescence 
stainings. 
 
 
 
Figure 22: Experimental outline of publication III. Schematic overview on the experimental design 
of the manuscript entitled: A new model for preclinical testing of dermal substitutes for human skin 
reconstruction. 
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3.4.4 Publications IV + V 
 
Skingineering I: Engineering porcine dermo-epidermal skin analogues for autologous 
transplantation in a large animal model 
Skingineering II: Transplantation of large-scale laboratory-grown skin analogues in a 
new pig model: 
One major disadvantage of the rat model is the small size of these animals. 
The skin substitutes transplanted onto the rats can only have a diameter of about 3 
cm. But considering envisioned future clinical trials, the engineered dermo-epidermal 
skin substitutes also have to be pre-clinically evaluated in a size and shape relevant 
for clinical application. Therefore, to circumvent the shortcoming of the rat model, we 
aimed in establishing a large animal model that allows the transplantation of large 
engineered skin substitutes. As porcine skin has shown to be the closest relative to 
human skin with regard to anatomy and physiology (180-181), we decided aiming for 
a porcine model. 
The pig allows to test skin substitutes of 49 cm2, but requires autologous 
porcine skin substitutes as these immuno-competent animals otherwise would reject 
the transplants (Figure 23). To set up a new animal model requires several steps: 
 
• Establishing a protocol to isolate and propagate porcine dermal fibroblasts 
and keratinocytes in the laboratory. 
• Investigate the potential of these cells to generate a dermo-epidermal skin 
substitute in vitro 
• Establishing a protocol for the transplantation of autologous skin 
substitutes to pigs, with regard to transplantation site, graft protection, and 
suitable wound dressing for these animals. 
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Figure 23: Experimental outline of publications IV and V. Schematic overview on the experimental 
design of the manuscripts entitled: Skingineering I: Engineering porcine dermo-epidermal skin 
analogues for autologous transplantation in a large animal model, and Skingineering II: 
Transplantation of large-scale laboratory-grown skin analogues in a new pig model. When working 
with the rat animal model, round skin substitutes of ~7 cm2 can be transplanted with cells of human 
origin, as the rats are immuno-incompetent. When working with the porcine animal model, square skin 
substitutes of 49 cm2 can be transplanted, but in contrast to the rat model, here the cells must be 
autologous cells for each animal. 
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4. RESULTS 
 
4.1 Collagen hydrogels strengthened by biodegradable meshes are 
a basis for dermo-epidermal skin grafts intended to reconstitute 
human skin in a one-step surgical intervention 
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Abstract 
 
Extensive full-thickness skin loss, associated with deep burns or other 
traumata, represents a major clinical problem that is far from being solved. A 
promising approach to treat large skin defects is the use of tissue-engineered full-
thickness skin analogues with nearly normal anatomy and function. In addition to 
excellent biological properties, such skin substitutes should exhibit optimal structural 
and mechanical features. This study aimed to test novel dermo-epidermal skin 
substitutes based on collagen type I hydrogels, physically strengthened by two types 
of polymeric net-like meshes. One mesh has already been used in clinical trials for 
treating inguinal hernia; the second one is new but consists of a FDA-approved 
polymer. Both meshes were integrated into collagen type I hydrogels and dermo-
epidermal skin substitutes were generated. Skin substitutes were transplanted onto 
immuno-incompetent rats and analyzed after distinct time periods. The skin 
substitutes homogeneously developed into a well-stratified epidermis over the entire 
surface of the grafts. The epidermis deposited a continuous basement membrane 
and dermo-epidermal junction, displayed a well-defined basal cell layer, about 10 
suprabasal strata and a stratum corneum. Additionally, the dermal component of the 
grafts was well vascularised. 
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Introduction 
 
Treatment of patients with extensive skin loss resulting from burns, soft tissue 
trauma, removal of congenital giant naevi and skin diseases still represents a major 
clinical problem that is far from being solved. None of the current therapeutic 
strategies, based on autologous split-thickness skin or cultured keratinocyte sheets 
transplanted onto dermal templates, such as Integra® or Matriderm®, yield truly 
satisfactory long-term functional and cosmetic results (Böttcher-Haberzeth et al., 
2010; Gobet et al., 1997; Pandya et al., 1998; Schneider et al., 2009). 
Hypothetically, a significant improvement may be reached by the use of a 
tissue-engineered, autologous full-thickness skin analogue to replace the missing 
skin. 
Apart from exhibiting superb biological features, the skin substitute should 
possess adequate mechanical properties to allow easy handling by surgeons, permit 
sewing to the wound site and resist, to a certain extent, shear forces exerted on the 
area of transplantation (e.g. joint areas) (van der Veen et al., 2009). Due to its 
advantageous properties, collagen type I proved to be an ideal matrix for skin tissue 
engineering in preclinical models (Böttcher-Haberzeth et al., 2012; Braziulis et al., 
2010; Faraj et al., 2007; Kinikoglu et al., 2009; Schiestl et al., 2010). This is in 
contrast to collagen sponges, such as Integra Dermal Regeneration Template® 
(Schiestl et al., 2011; Stiefel et al., 2010) and Matriderm® (Ryssel et al., 2008; van 
Zuijlen et al., 2000), into which and onto which it is difficult, if not impossible, to seed 
and grow skin cells. In contrast, collagen hydrogels mimic the natural extracellular 
matrix (ECM) of dermal fibroblasts, thereby significantly supporting their proliferation, 
migration and differentiation (Drury and Mooney, 2003; Elisseeff, 2008; Oh et al., 
2012). In addition, fibroblasts can be submerged and evenly distributed within such a 
hydrogel. Markedly supported by the underlying fibroblasts, keratinocytes will 
proliferate on such gels and develop into a stratified epidermis (Bell et al., 1981; 
Parenteau et al., 1992; Stark et al., 2004). Due to the excellent biological properties 
of collagen hydrogels, dermo-epidermal grafts can be generated. Most importantly, 
these can be applied in only one surgical intervention (instead of two successive 
operations). Since in this procedure skin cells are massively expanded, the donor site 
for the biopsy is very small. In large burns, the availability of large enough donor sites 
is frequently a serious problem. 
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Major disadvantages of collagen hydrogels, however, are their physical 
weakness, contraction and degradation in combination with cells (Krishnan et al., 
2004). However, it has been shown that these problems can be circumvented by 
varying collagen concentrations (Helary et al., 2010, 2011, 2012). Even more 
importantly, significantly improved stability of collagen hydrogels was reached by 
plastic compression (Hu et al., 2010; Levis et al., 2010), even allowing the 
construction of large, clinically relevant (49 cm2) dermo-epidermal skin substitutes 
(Braziulis et al., 2012) and collagen gel tubes (Micol et al., 2011). Nevertheless, 
additional increased mechanical stability of skin substitutes is desirable to be able to 
fix them on the patient by sewing or stapling and to provide optimal handling 
characteristics. This can be achieved by the incorporation of a net-like mesh. 
A long-term, resorbable, net-like fabric (TIGRW Surgical Mesh) was developed 
by the Swedish company Novus Scientific (Hjort et al., 2012). Based on its 
mechanical properties and its successful outcome in clinical trials, we assume that it 
also has high potential with regard to reinforcing our tissue-engineered skin 
substitutes. The fabric is a knitting of two types of fibres: fibre 1 consists of a co-
polymer of trimethylene carbonate and lactide; fibre 2 consists of a co-polymer of 
trimethylene carbonate, lactide and glycolide. For the present study, the fibres of type 
2 of this mesh were removed (leading to a modified TIGRW Surgical Mesh, referred 
to below as knitted mesh), as mainly stability over a longer time period was desired. 
A second material showing high potential for application in skin tissue 
engineering is poly(lactic-co-glycolic acid) (PLGA). This co-polymer can be seeded 
with human skin fibroblasts (Chen et al., 2005) and is FDA-approved. It is 
synthesized by means of random ring-opening copolymerization of two different 
monomers, viz. glycolic acid and lactic acid, and has good biodegradability, suitable 
biodegradation kinetics, good mechanical properties and a certain ease of 
processing (Kumbar et al., 2008; Lu et al., 2009). A mesh-like PLGA sheet has been 
produced by aap Bioimplant. This electrospun mesh (as it is referred to below) exerts 
good biological characteristics and mechanical stability. 
The goal of this study was to develop skin analogues exhibiting optimal 
biological and, in particular, also mechanical properties. The latter should be realized 
by including a biodegradable, net-like scaffold into the collagen hydrogel that 
eventually makes up the dermal part of a dermo-epidermal skin substitute. The 
scaffolds used are supposed to easily incorporate into a collagen hydrogel and 
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provide a maximum of stability for the time point of transplantation and the first period 
after transplantation, but thereafter should start to degrade without harming the 
surrounding tissue by their degradation products. 
 
RESULTS – PUBLICATION I 
52 
Materials and Methods 
 
Biodegradable matrices: knitted mesh 
The biodegradable knitted mesh (TIGRW Surgical Mesh) used in the study 
was kindly provided by Novus Scientific (Uppsala, Sweden). The mesh was originally 
made from two different multifilaments: multifilament 1 was made from a co-polymer 
of trimethylene carbonate and lactide and showed slow degradation kinetics, with 
good stability over a 9 month period; multifilament 2 was made from a co-polymer of 
trimethylene carbonate, lactide and glycolide, showed relatively fast degradation 
kinetics and was completely degraded after 6 months. The mesh was tested for 
biocompatibility according to the requirements found in standard ISO 10993-1. As the 
fibres of type 2 comprise about 40 wt% of the mesh, these fibres were removed for 
the present study by incubation of the mesh in an aqueous solution of 34.85 g/l 
dipotassium phosphate, pH 12, for 5 days, leaving a mesh composed only of fibres of 
type 1, viz. fibres of a co-polymer of trimethylene carbonate and lactide behind 
(Figure 1a). The knitted mesh consists of a co-polymer of trimethylene carbonate and 
lactide, with good stability over a period of at least 9 months (unpublished data from 
Novus Scientific). It has been shown that full resorption of the fibres is reached after 
36 months (Hjort et al., 2012). Additionally, it has been shown that 4 months post 
implantation the mesh was surrounded by a moderate grade of fibrous tissue and 
induced an inflammatory reaction, similar to the reaction observed with a control 
mesh. At 15 and 24 months, the mesh induced a higher inflammatory reaction than 
the control mesh, with mainly higher recruitment of phagocytic cells, which is part of 
the degradation process, as evidenced by fibres displaying signs of degradation 
(Hjort et al., 2012). At 4, 9, 24 and 36 months after implantation the mesh was well 
integrated, without signs of encapsulation (Hjort et al., 2012). 
 
Biodegradable matrices: electrospun mesh 
The biodegradable electrospun mesh used in the present study was kindly 
provided by F. Yang (Department of Biomaterials, Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands). The biodegradable electrospun mesh 
(Figure 1b) is made of poly(lactic-co-glycolic acid) (PLGA; PURAC Biochem bv, 
Gorinchem, The Netherlands). Detailed procedures are described in Supplementary 
materials and methods (see Supporting information). 
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The ratio glycolide:lactide determines the degradation time of a poly(lactic-co-
glycolic acid) polymer, with increasing percentages of lactide increasing the 
degradation time. However, the fastest degradation time was seen in PLGA with a 
ratio of 50:50 (Makadia and Siegel, 2011). The material used for this study was 
composed of PLGA in a ratio of 52:48 (52% D,L-lactide and 48% glycolide). 
Therefore, it was expected that this material exhibited a somewhat slower 
degradation than the 50:50 PLGA material, with an in vitro half-life of about 3-4weeks 
(Lu et al., 2000). 
 
Cell isolation and culture 
Human full-thickness skin biopsies were obtained after informed consent of 
the patient or parents. Human primary fibroblasts and keratinocytes were isolated 
and cultured as previously described (Biedermann et al., 2010; Kiowski et al., 2012; 
Pontiggia et al., 2009). Detailed procedures are described in Supplementary 
materials and methods (see Supporting information). 
 
Engineering of dermo-epidermal skin substitutes 
Organotypic cultures for a dermo-epidermal skin substitute were prepared as 
earlier described (Pontiggia et al., 2009), using a previously established transwell 
system (six-well cell culture inserts with membranes of 3 mm pore size; BD Falcon, 
Basel, Switzerland). Briefly, membranes were covered with either the knitted mesh 
(Figure 2a) or the electrospun mesh (Figure 2b). Subsequently, a solution of bovine 
collagen type I (BD Biosciences, Basel, Switzerland) was mixed with 1x105 human 
primary dermal fibroblasts and neutralized with a buffer containing NaOH (Costea et 
al., 2003) just before pouring the solution on the scaffolds. Additionally, constructs 
were engineered without any scaffold incorporated as internal control (Figure 2c). 
After performing compression according to Braziulis et al. (Braziulis et al., 2012; 
Brown et al., 2005), the hydrogels were cultured for 5 days in fibroblast growth 
medium before seeding 7.5x105 keratinocytes onto the complete surface of the 
hydrogels. After initial submersed cultivation in Rheinwald and Green keratinocyte 
differentiation medium (RGM) (Rheinwald and Green, 1975) for 3 days, the medium 
level was lowered to expose the developing epidermis to air (air–liquid interface; 
Gauvin et al., 2012) for an additional 3 days before transplantation of the constructs 
onto immuno-incompetent rats. Medium changes were performed every 2–3days. 
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Fluorescein diacetate live cell staining 
Fluorescein diacetate (FdA; Sigma, Buchs, Switzerland) staining was 
performed to determinate cell viability, as previously described (Armour et al., 2008; 
Jones and Senft, 1985). Briefly, the cell culture medium was removed and replaced 
with a dilution of 5 mM FdA in PBS (Invitrogen) for 2 min. FdA solution was removed 
by washing twice with PBS and was replaced by RGM. Fluorescein fluorescence was 
evaluated using microscopy (Nikon SMZ1500 fluorescent stereo microscope, FITC 
filter, Nikon DXM1200F camera). 
 
Transplantation of dermo-epidermal skin substitutes 
All animal experiments were approved by the local Committee for 
Experimental Animal Research. Dermo-epidermal skin substitutes were transplanted 
onto full-thickness skin defects created surgically on the backs of immuno-
incompetent female nu/nu rats, aged 8–10 weeks (Harlan, Horst, The Netherlands), 
as previously described (Biedermann et al., 2010; Kiowski et al., 2012). The animal 
numbers were: skin substitutes with knitted mesh, n=7 (Figure 2a); skin substitutes 
with electrospun mesh, n=7 (Figure 2b); skin substitutes without mesh, n=7 (Figure 
2c). All animals survived the procedure and the 3weeks post transplantation. A steel 
ring, 27 mm in diameter, was used as a modified Fusenig chamber (Fusenig et al., 
1983) and the transplants were covered with silicon foil. Three weeks after 
transplantation, all the animals were sacrificed and the grafts excised and processed 
for cryo- and paraffin sections. For that, samples were halved and either embedded 
in OCT compound (Tissue-Tek®, Sakura Finetek, Japan) or fixed in 4% 
paraformaldehyde (Medite Medizintechnik AG, Nunningen, Switzerland) and 
embedded in paraffin (McCormick, Richmond, USA). 
 
Histology and immunofluorescence 
Paraffin-embedded tissue was sectioned by microtome (Leica, Wetzlar, 
Germany), and 10 mm sections were stained with haematoxylin and eosin (H&E; 
Sigma) and imaged by light microscopy. OCT compound-embedded tissue was used 
for cryosections (Leica) and 10 mm sections were used for indirect 
immunofluorescence. Detailed procedures are described in Supplementary materials 
and methods (see Supporting information). 
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Fluorescence microscopy 
Immunofluorescence stainings were analyzed using a Nikon Eclipse TE2000-
U inverted microscope with Hoechst, FITC and TRICT filter sets connected with a 
DXM1200F digital camera (Nikon AG, Egg, Switzerland). Images were processed 
with Photoshop 7.0 (Adobe Systems, Munich, Germany). 
 
Scanning electron microscopy 
Scanning electron microscopy (SEM) was performed at the Centre for 
Microscopy and Image Analysis (University of Zurich, Switzerland). Detailed 
procedures are described in Supplementary materials and methods (see Supporting 
information). 
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Results 
 
Knitted and electrospun meshes integrate into collagen type I hydrogels 
We investigated two different polymer meshes and their integration into 
plastically compressed collagen type I hydrogels. One of these meshes consisted of 
a slow degrading multifilament produced using a co-polymer of trimethylene 
carbonate and lactide (Figure 1a). Scanning electron microscopy (SEM) revealed 
interwoven bundles of about 20 polymer fibres, creating a physically resistant porous 
mesh (Figure 1c). The second mesh was an electrospun fabric consisting of 52% 
D,L-lactide and 48% glycolide, with a molecular weight of 153 000; poly(lactic-co-
glycolic acid) (PLGA) (Figure 1b). SEM showed that the individual fibres of this mesh 
were arranged in a nonwoven manner and mostly orientated unidirectionally (Figure 
1d). 
SEM of both fibres incorporated in collagen type I hydrogels showed solid 
incorporation of the polymer meshes into the collagen hydrogels (Figure 1e, f). The 
hydrogels surrounded the fibres in all directions; fibres were only visible at the 
borders of the samples where the samples were cut (Figure 1e, f, white arrowheads). 
 
Dermo-epidermal skin grafts strengthened by biodegradable meshes 
Our goal was to develop highly functional dermo-epidermal skin substitutes 
that can be optimally applied onto the patient. Cell survival, proliferation, 
differentiation and epidermal stratification in vitro were evaluated by fluorescein 
diacetate (FdA) live-cell staining and additional histological analyses. 
FdA stainings of a dermo-epidermal skin substitute with knitted mesh 
incorporated into its dermal part were performed at two different time points. These 
stainings showed that the keratinocytes seeded on this hydrogel do not form a 
confluent layer 1 day after seeding (Figure 3a), but during a cultivation phase of 2–3 
days they proliferate and develop into a confluent cell layer 
(Figure 3c). 
Similar FdA stainings were performed with collagen type I hydrogels 
containing fibroblasts and the incorporated electrospun mesh. Here also, the 
keratinocyte layer was not confluent 1 day after keratinocyte seeding (Figure 3b). 
After an additional 2–3 day cultivation phase, the keratinocytes proliferated and 
formed a confluent cell layer, as FdA staining confirmed (Figure 3d). 
RESULTS – PUBLICATION I 
 57 
The presence of an epidermis, consisting of two or three layers of 
keratinocytes, on the dermo-epidermal skin substitute with incorporated knitted mesh 
was also confirmed using H&E staining (Figure 3e). In the dermal part, fibroblasts 
and remnants of the knitted mesh were detectable (Figure 3e, black arrowheads). On 
H&E stained cryosections of the skin substitutes with incorporated electrospun mesh, 
similar results were obtained, showing a two- or three-layered epidermis on top of a 
fibroblast-containing dermal part with remnants of the electrospun mesh (Figure 3f, 
black arrowheads). 
In addition to the suitability of the mesh to allow cell survival and proliferation, 
the collagen hydrogel containing the knitted mesh also showed excellent handling 
properties and smoothly adapted to a given underlying shape, as both round patches 
of 2.5 cm diameter and square skin substitutes of 7x7 cm (Figures 3g, h, 4a). 
 
Testing dermo-epidermal skin substitutes in vivo 
The dermo-epidermal skin substitutes were tested in an animal model on full-
thickness skin defects of approximately 5 cm2. Substitutes containing the two 
different types of scaffolds (Figure 4a, c) were transplanted onto the backs of 
immuno-incompetent (nu/nu) rats. A modified Fusenig chamber was used to prevent 
wound closure by the ingrowth of adjacent rat skin (Figure 4b, d). Three weeks after 
transplantation, the grafts were excised and the specimens were examined 
histologically. Macroscopic analyses revealed a homogeneous skin-like appearance 
on the entire grafted area (Figure 4b, d). H&E staining confirmed the macroscopic 
impression and revealed that dermo-epidermal skin substitutes with either of the 
meshes exhibited a well-stratified, continuous epidermis that had developed over the 
entire surfaces of the grafts, including a stratum corneum (Figure 4e–h). The results 
were comparable to grafts without any reinforcing mesh (Figure 4i). Remnants of 
both meshes were detected for both scaffold types in correspondence with the 
degradation times of these scaffolds. The development of the epidermis was 
supported by ingrowing blood vessels originating in the underlying dermal tissue, as 
revealed by higher magnification pictures (Figure 4g, h). Blood vessels not only grew 
into the dermo-epidermal skin substitutes, but were also found in close proximity to 
remnants of the mesh (Figure 4g, h), thus underlining the non-toxic properties of the 
scaffolds. 
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Characterization of dermo-epidermal skin substitutes 
To evaluate the quality of the skin developed from the transplanted dermo-
epidermal skin substitute, immunofluorescence staining was performed using a set of 
established markers for wound healing and skin homeostasis. 
Cytokeratin 1 (K1) is expressed in all suprabasal keratinocyte layers in normal 
homeostatic skin. This was also observed in both types of transplants, as well as in 
the control, 3weeks after transplantation (Figure 5a–c). Deposition of the basal 
lamina was detected by using an antibody to laminin 5 (Figure 5a–c). In combination, 
these stainings revealed that a state close to homeostasis was reached, showing a 
stratum basale typically not expressing K1 (just the blue nuclei stained by Hoechst 
dye are visible) and the suprabasal, K1-positive keratinocyte layers (Figure 5a-c). 
Just as in healthy human skin, cytokeratin 15 (K15) was exclusively expressed in 
basal keratinocytes anchored to a functional basal lamina (Figure 5d–f). In healthy 
skin of very young children (up to 1.5 years), a subpopulation of K15-expressing 
basal cells is positive for cytokeratin 19 (K19) (Pontiggia et al., 2009). In accordance 
with this, 3weeks after transplantation, a subset of K15-positive cells were found to 
express K19 (Figure 5d–f), indicating a young and self-renewing subset of 
keratinocytes in the stratum basale. As seen in Figures 5d, e, some of the K19-
positive keratinocytes were still detectable in suprabasal layers, indicating that the 
final homeostatic state was not yet established. This, however, was not surprising at 
such an early stage after transplantation. Double staining using a human-specific 
fibroblast marker (CD90) and a rat-specific blood vessel marker (CD31) revealed that 
blood vessels of rat origin grew into the dermal part of the grafted skin substitute 
within 21 days, thereby ensuring proper humoral support of the epidermis (Figure 
5g–i). Notably, employing the melanosome marker HMB45 proved that human 
melanocytes, co-cultured with human keratinocytes in both matrix-supported collagen 
hydrogels, not only survived in the three-dimensional (3D) skin substitutes but were 
maintained in physiological numbers within the basal cell layer for the period of 
investigation (Figure 5j–l). 
Taken together, it can be said that the included net-like scaffolds only 
moderately, if at all, slowed down the development of epidermal homeostasis in the 
tested dermo-epidermal substitutes. In summary, these results revealed that the 
developed epidermis was well stratified but, nevertheless, was not yet in a 
completely homeostatic situation. 
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Scanning electron microscopy analysis 
Scanning electron microscopy (SEM) was performed with specimens of the 
grafted dermo-epidermal skin substitutes 21 days after transplantation. Punch 
biopsies were taken after excision of the grafts and cross-sections of the biopsies 
were processed for SEM. 
An overview showing the general appearance of the skin substitute with the 
knitted mesh is shown in Figure 6a. Fibres of this mesh were quite prominent in the 
dermal part of this skin substitute and an intact epidermis was evident (Figure 6a, 
white arrow). Skin substitutes containing the electrospun mesh exhibited scaffold 
remnants that appeared as melted bulbs, which are artefacts due to the SEM 
preparation procedure (Figure 6b and insert). Nevertheless, the electrospun mesh 
required less space than the knitted mesh (Figure 6a, b). Higher magnifications of the 
skin substitutes with the incorporated knitted mesh revealed the high content of 
collagen fibres in the dermal part. Interestingly, collagen fibres were found not only 
around the fibre bundles of the knitted mesh but also in close association with the 
individual mesh fibres, providing evidence for a very good incorporation of the mesh 
into the substitute (Figure 6c). Higher magnification of the skin substitute with 
electrospun mesh showed a well-structured epidermis, including a tight basal cell 
layer, several suprabasal layers and the squamous stratum corneum (Figure 6d). In 
accordance with the data presented in Figures 4g, h, 5g, h, SEM also revealed that 
blood vessels were located in close proximity to both types of mesh fibres (Figure 6e, 
f and inserts in 6e, f). 
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Discussion 
 
The treatment of massive full-thickness skin defects with tissue-engineered 
skin grafts has shown promise in preclinical studies and clinical trials. Most of these 
skin grafts comprised fibroblasts and/or keratinocytes grown on collagen ’sponges’, 
generated by freeze-drying (Boyce et al., 1995). These sponges, however, hardly 
permit fibroblasts to reach the inner sponge pores; thus, an even distribution of these 
cells is almost impossible (Powell et al., 2008). In addition, these porous structures 
represent a barrier for cells and factors that induce essential signals for the 
epidermis–dermis crosstalk. This is a significant disadvantage, as fibroblasts are 
essential to promote epidermal cell survival, proliferation and differentiation (El 
Ghalbzouri et al., 2002). Thus, a biologically ideal collagen type I hydrogel with 
incorporated fibroblasts represents a valid dermal template for a skin substitute. 
Indeed, the living fibroblasts in the substitute create a cell-instructive environment 
which constantly produces and releases a physiological set of biologically active 
growth factors, cytokines and matrix components in physiological concentrations 
(Braziulis et al., 2012; Pontiggia et al., 2009; Schneider et al., 2010). A recently 
published related approach is based on the same elegant idea of employing a 
synthetic degradable mesh to stabilize a compressed hydrogel (Ananta et al., 2012). 
It describes a living allogenic wound dressing. Since this wound dressing will be 
immunologically removed with time, it will transiently support wound healing. Notably, 
these authors state that the presence of keratinocyte layers on this dressing may not 
be essential for skin wound healing (Ananta et al., 2012). 
In contrast, our goal was the generation of an autologous skin graft, to be 
applied as a permanent skin substitute. Clearly, this skin graft requires both a 
functional dermal and epidermal component. Here we present a method that 
combines the excellent biological properties of a skin substitute, based on a 
plastically compressed collagen type I hydrogel, with the mechanical support 
provided by a degradable mesh, and the possibility of surgically fixing this skin graft 
on the wound site. We found that an electrospun mesh made of poly(lactic-co-
glycolic acid), as well as a knitted mesh composed of a co-polymer of trimethylene 
carbonate and lactide, could easily be incorporated into collagen type I hydrogels. 
Neither mesh interfered with cell survival and proliferation in vitro and in vivo. Both 
meshes allowed the development of a normally stratified epidermis with a basal 
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lamina, several suprabasal cell layers and a stratum corneum in vivo. The substitutes 
survived for at least 3weeks in vivo, indicating that they were nourished by ingrowing 
blood vessels of recipient (rat) origin. In an early state of organ reconstitution, the 
engineered dermo-epidermal skin substitutes expressed a characteristic set of 
established, skin-specific wound-healing markers (Biedermann et al., 2010; Pontiggia 
et al., 2009). At later stages, markers indicating the establishment of skin tissue 
homeostasis became expressed. The pattern of these markers was similar to the one 
found in well-regenerated skin. An identical pattern of markers was found in 
hydrogel-based grafts generated without any stabilizing meshes. 
The skin graft containing the knitted mesh could be handled more 
conveniently than the substitute with the electrospun mesh; the first fitted ideally and 
adhered more smoothly to a given wound surface. This might be a result of the 
higher flexibility and higher total volume of the mesh inside the graft. 
We therefore propose that a knitted mesh is probably the best choice currently 
available. However, the number of fibres may still be reduced (as compared to the 
one described herein), so that the ideal timing between the initial tissue 
reinforcement and the subsequent mesh degradation can be realized. 
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Figures 
 
 
Figure 1. Microscopical analyses of knitted and electrospun meshes: light microscopic view of (a) the 
knitted and (b) the electrospun meshes; (c) single fibres of the knitted mesh revealed by SEM; (d) the 
dense network of fibres in the electrospun mesh revealed by SEM; (e, f) SEM micrographs of collagen 
type I hydrogels surrounding the incorporated meshes. White arrowheads, fibres of the two different 
scaffolds. Scale bars = 1mm (a, b, e); 10mm (c); 20mm (d); 200mm (f) 
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Figure 2. Schematic representation of experimental design. Human full-thickness skin biopsies are 
used to isolate human primary fibroblasts and keratinocytes. Dermo-epidermal skin substitutes are 
generated with either: (a) incorporated knitted mesh; (b) incorporated electrospun mesh; or (c) no 
incorporated scaffold. The dermo-epidermal skin substitutes were transplanted onto the back of 
immuno-incompetent rats. Three weeks post-transplantation, the grafts were excised and analysed. 
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Figure 3. In vitro properties of the dermo-epidermal skin substitutes stabilized by the two different 
meshes. (a–d) Live cell staining of keratinocyte layers using fluorescein diacetate: (a, b) on both 
grafts, 1 day after keratinocyte seeding, the keratinocytes did not form a confluent layer; white arrows, 
areas with holes in the keratinocyte layer; (c, d) on both grafts, keratinocytes have proliferated into 
confluent cell layers 2–3 days after seeding. (e, f) H&E staining of histological sections of the skin graft 
containing (e) the knitted and (f) the electrospun meshes, 7 days after keratinocyte seeding. Black 
arrowheads, remnants of the polymeric fibres. (g, h) Macroscopic views of the construct with the 
knitted mesh demonstrate its excellent handling properties. Scale bars=1 mm (a–d); 100mm (e); 
50mm (f); 1cm(g) 
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Figure 4. Stabilized dermo-epidermal skin substitutes in vivo. Macroscopic view of the skin substitute 
containing the knitted mesh (a) before and (b) 3weeks after transplantation onto immuno-incompetent 
nude rats, showing its highly organotypic appearance. (c, d) Corresponding macroscopic views of the 
substitute with the electrospun mesh. (e, f) H&E-stained sections of the two types of grafts, 21 days 
after transplantation, reveals a well-stratified epidermis. Black arrowheads, remnants of the scaffolds; 
arrows, stratum corneum. (g, h) Higher magnifications showing ingrown blood vessels (white 
arrowheads) in close proximity to scaffold remnants (black arrowheads). (i) Histology of a control 
dermo-epidermal skin substitute without any reinforcing mesh reveals a well-stratified epidermis. Scale 
bars=1cm (a–d); 100mm (e, f, i); 50mm (g, h) 
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Figure 5. Immunofluorescence analyses of the dermo-epidermal skin substitutes with either knitted or 
electrospun mesh or without any reinforcing mesh, excised 21 days after transplantation. (a–c) In 
accordance with the normal physiology, cytokeratin 1 (green) is expressed in all suprabasal layers of 
the grafts, while the basal layer is excluded. Laminin 5 staining (red) reveals deposition of a 
continuous basement membrane. (d–f) Staining for cytokeratin 15 (green) reveals restriction of K15 
expression to basal cells, whereas cytokeratin 19 (red) expression is mostly found in basal cells but 
also still in some suprabasal keratinocytes. (g–i) Human dermal fibroblasts (green) are recognized by 
the human CD90 (Thy-1)-specific antibody, whereas the rat tissue is not stained, CD31 (red) is 
specifically expressed in blood vessels of rat origin, ingrown into the dermal part of the substitute. (j–l) 
Staining of human melanocytes withHMB-45 (green) and co-staining of laminin 5 (red) reveals human 
melanocytes maintained in physiological numbers in the basal cell layer of the substitutes. (a–l) Nuclei 
are stained with Hoechst dye (blue). Scale bars=50mm (a–f, h–l); 100mm (g) 
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Figure 6. Scanning electron microscopy of dermo-epidermal skin substitutes containing either the 
knitted or the electrospun mesh, excised 21 days after transplantation. (a) Dermo-epidermal skin 
substitute containing knitted mesh shows an intact epidermis (white arrow); white arrowhead, fibres of 
the knitted mesh in the dermal part of the skin substitute. (b) Likewise, the substitute with electrospun 
mesh shows a well-stratified epidermis (white arrow). Mesh fibres are detectable as melted bulbs, due 
to preparation artefacts (white arrowhead and insert). (c) Distribution of collagen fibres around and 
between single mesh fibres. (d) Higher magnification shows organization of the epidermis (white 
arrow), several suprabasal cell layers and a prominent stratum corneum (arrowhead). (e, f) Higher 
magnifications show blood vessels in close proximity to the fibres of the knitted and electrospun 
meshes. Arrowheads, remnants of meshes. Scale bars=100mm (a, b, e); 20mm (c); 10mm (d, e insert, 
f); and 2mm (f insert) 
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4.2 Human amniotic fluid derived cells can competently substitute 
dermal fibroblasts in a tissue-engineered dermo-epidermal skin 
analog 
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Abstract 
 
Purpose Human amniotic fluid comprises cells with high differentiation 
capacity, thus representing a potential cell source for skin tissue engineering. In this 
experimental study, we investigated the ability of human amniotic fluid derived cells 
to substitute dermal fibroblasts and support epidermis formation and stratification in a 
humanized animal model. 
Methods Dermo-epidermal skin grafts with either amniocytes or with 
fibroblasts in the dermis were compared in a rat model. Full-thickness skin wounds 
on the back of immuno-incompetent rats were covered with skin grafts with (1) 
amniocytes in the dermis, (2) fibroblasts in the dermis, or, (3) acellular dermis. Grafts 
were excised 7 and 21 days post transplantation. Histology and immunofluorescence 
were performed to investigate epidermis formation, stratification, and expression of 
established skin markers. 
Results The epidermis of skin grafts engineered with amniocytes showed 
near-normal anatomy, a continuous basal lamina, and a stratum corneum. 
Expression patterns for keratin 15, keratin 16, and Ki67 were similar to grafts with 
fibroblasts; keratin 1 expression was not yet fully established in all suprabasal cell 
layers, expression of keratin 19 was increased and not only restricted to the basal 
cell layer as seen in grafts with fibroblasts. In grafts with acellular dermis, 
keratinocytes did not survive. 
Conclusion Dermo-epidermal skin grafts with amniocytes show near-normal 
physiological behaviour suggesting that amniocytes substitute fibroblast function to 
support the essential cross-talk between mesenchyme and epithelia needed for 
epidermal stratification. This novel finding has considerable implications regarding 
tissue engineering. 
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Introduction 
 
The composition of the amniotic fluid changes with gestational age. Whereas 
in the first half of gestation most of the fluid comes from active sodium and chloride 
transport across the amniotic membrane and the fetal skin, most of the fluid in the 
second half of gestation results from fetal micturition and lung water production [1]. 
The cells found in this fluid stem from all three germ layers and stem from the fetal 
skin, the digestive tract, and from the amniotic membranes [2]. Among the 
heterogeneous population of fetal cells that can be found in the amniotic fluid are 
mesenchymal, hematopoietic, epithelial, and trophoblastic cells [3]. 
Previous studies showed that the mesenchymal cells from the amniotic fluid 
(in this study, referred to as amniocytes) express a phenotypic profile that is 
consistent with the profile of fetal mesenchymal progenitor cells, i.e., they are 
negative for CD31 and positive for vimentin, α-smooth muscle actin, keratin 8 and 18, 
and fibroblast surface protein [4, 5]. They express several, but not all, important 
markers for embryonic stem cells, i.e., they are positive for Oct-4, Nanog, and SSEA-
4, indicating that they represent a new class of stem cells, situated between 
embryonic stem cells and adult stem cells [3, 6]. It was shown that amniocytes have 
an expansion capacity four to eightfold higher than bone marrow derived 
mesenchymal stem cells, and that they differentiate into various mesenchymal 
lineages, including fibroblasts, osteocytes, and adipocytes [7]. In culture, these cells 
secrete various cytokines and chemokines important for wound healing, such as IL-6, 
IL-8, TGF-b, TNFRI, VEGF, and EGF [8]. Culturing of these cells was successful over 
a period of 8 months with stable karyotype [9]. In addition, it was shown that 
amniocytes retain their proliferative capacity and differentiation potential also during 
decades of cryopreservation [10]. 
Autologous fetal tissue engineering was performed in different animal models 
for various postnatal surgical interventions such as bladder augmentation, 
diaphragmatic replacement, tracheal augmentation, and skin defects [11–14]. Of 
note, in these models, tissue engineering was performed using a biopsy from the 
respective organ and the engineered tissue was delivered only after birth. 
For fetal tissue engineering purposes, the amniotic fluid is a very attractive cell 
source. Cells can easily be harvested from amniotic fluid aspirated during the 
frequently performed diagnostic amniocenteses [5]. The goal of this paper was to test 
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whether amniocytes could be used for tissue engineering of skin. In particular, we 
wanted to investigate whether these amniocytes finally can assume anatomically and 
functionally the role of dermal fibroblasts. 
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Materials and Methods 
 
Cell harvest and culture 
Human skin samples were obtained after informed consent from patients 
and/or parents; all described studies were approved by the Medical Ethical 
Committee of the Kanton Zurich. Human primary fibroblasts and keratinocytes were 
isolated and cultured according to the standard protocol as previously described [15]. 
Confluent back-up human amniocentesis cultures were received after 
informed consent of the patients from the clinical cytogenetics laboratory of the 
University Medical Center Groningen. Cells were cultured from healthy fetuses (with 
a normal karyotype). Cells were harvested and expanded in DMEM (Lonza, Breda, 
The Netherlands) supplemented with 20 % fetal calf serum (FCS; Perbio Science, 
Ettenleur, The Netherlands) and 1 % penicillin, 1 % streptomycin (10,000 U/ml, 
Gibco, Paisley, UK), and 2 mM L-glutamine (Lonza, Breda, The Netherlands). 
 
Engineering of dermo-epidermal skin substitutes 
Skin grafts with either normal human dermal fibroblasts or human amniocytes 
in the dermis were prepared, using a previously established transwell system [6-well 
cell culture inserts with membranes of 3 µm pore-size (BD Falcon, Basel, 
Switzerland)] [15–17]. As negative control, skin substitutes with an acellular dermis 
were produced. 
Briefly, bovine collagen type I (BD Biosciences, Basel, Switzerland) was mixed 
with either 1 x 105 human primary dermal fibroblasts or with 1 x 105 human 
amniocytes, or, for the negative control, no cells, and neutralized with a buffer 
containing NaOH [18]. The solution was poured into the cell culture inserts. The 
hydrogels were plastically compressed [19] and cultivated in DMEM with 10 % FCS. 
After 5 days, 7.5 x 105 keratinocytes were seeded onto the complete surface of all of 
the hydrogels. The grafts were cultivated for 3 days under submersed conditions in 
Rheinwald and Green keratinocyte medium, followed by 3 days cultivation at the air–
liquid interface before transplantation onto immuno-incompetent rats. Medium was 
changed every 2–3 days. 
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Bright light microscopy 
To compare the morphology of amniocytes and fibroblasts, bright light 
microscopic pictures were taken using a Nikon SMZ1500 stereo microscope with a 
Nikon DXM1200F camera. 
 
Fluorescein diacetate live cell staining 
The viability and morphological shape of the cells incorporated into the 
collagen type I hydrogels was compared using fluorescein diacetate (FdA) live cell 
staining [20]. Cell culture medium was removed and the hydrogels were incubated 
with 5 µM FdA (Sigma, Buchs, Switzerland) in PBS (Invitrogen, Basel, Switzerland). 
After 2 min, the FdA solution was removed and the hydrogels were washed with 
PBS. Fluorescein fluorescence was observed using a Nikon SMZ1500 fluorescent 
stereo microscope (FITC filter, Nikon DXM1200F camera). 
 
Transplantation of dermo-epidermal skin grafts 
Animal experiments were approved by the local committee for Experimental 
Animal Research. Immuno-incompetent nu/nu rats (age 8–10 weeks, Harlan, Horst, 
The Netherlands) were prepared as previously described [16, 17, 21, 22]. To prevent 
wound closure by the surrounding skin, steel rings (diameter 26 mm) were implanted 
into full-thickness skin defects on the back of the rats and served as a modified 
Fusenig chamber [23]. The transplants were inserted into the ring and covered with a 
silicon foil (Silon-SES, BMS, Allentown, PA, USA). Animal numbers were: amniocyte-
grafts excised 7 days post transplantation (n = 6); amniocyte-grafts excised 21 days 
post transplantation (n = 6); fibroblast-grafts excised 7 days post transplantation (n = 
6); fibroblast-grafts excised 21 days post transplantation (n = 6); grafts with acellular 
dermal part excised 21 days post transplantation (n = 6). Wound dressing changes 
and photographic documentations (Nikon D90) were performed every 7 days. 
Animals were killed 7 or 21 days post transplantation. Transplants were excised, 
halved, and embedded in O.C.T compound (Tissue-Tek®, Sakura Finetek, Japan), or 
fixed in 4 % paraformaldehyde (Medite Medizintechnik AG, Nunningen, Switzerland) 
and embedded in paraffin (McCormick, Richmond, USA). 
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Histology and immunofluorescence 
Paraffin sections (sectioned at 10 µm with a microtome from Leica, Wetzlar, 
Germany) were deparaffinised and stained with haematoxylin & eosin (Sigma, 
Buchs, Switzerland) and imaged by light microscopy (Nikon Eclipse TE2000-U 
inverted microscope connected with a DXM1200F digital camera (Nikon AG, Egg, 
Switzerland). 
O.C.T-embedded tissue was frozen at -20 °C and sectioned at 10 µm (Leica, 
Wetzlar, Germany). Sections were permeabilised in ice-cold acetone for 5 min, air-
dried, and washed three times with phosphate buffered saline (PBS, Invitrogen, 
Basel, Switzerland). Blocking was performed with PBS containing 2 % bovine serum 
albumin (Sigma, Buchs, Switzerland) for 30 min at room temperature. Sections were 
incubated with the pre-labelled antibodies for 1 h at room temperature. After three 
washing steps with PBS, nuclei were stained with 1 µg/ml Hoechst 33341 (Sigma, 
Buchs, Switzerland) in PBS for 5 min at room temperature. After two final washing 
steps with PBS, sections were mounted with Dako fluorescent mounting solution 
(Dako, Baar, Switzerland). 
 
Antibodies 
The following antibodies were used: K1 (clone LHK1, 1:200, Novus 
Biologicals, Littleton, USA); K15 (clone SMP190, 1:50, Spring Biosciences, Fermont, 
USA); K16 (clone LL025, 1:100, Chemicon International, Temecula, USA); K19 
(clone RCK108, 1:100, Dako, Glostrup, Denmark); Ki67 (clone B56, 1:100, ABD 
Serotec, Dusseldorf, Germany); Lam5a3 (clone P3H9-2, 1:100, Santa Cruz, Labforce 
AG, Nunningen, Switzerland) [24]. 
For immunofluorescence stainings, primary antibodies were pre-labelled with 
either Alexa488 or Alexa555 conjugated polyclonal goat F(ab’)2 fragments, according 
to the manufacturer’s instructions (Zenon Mouse IgG Labelling Kit, Molecular Probes, 
Invitrogen, Basel, Switzerland).  
 
Fluorescence microscopy 
Immunofluorescence stainings were analyzed using a Nikon Eclipse TE2000-
U inverted microscope, equipped with Hoechst, FITC and TRICT filter sets and 
connected with a DXM1200F digital camera (Nikon AG, Egg, Switzerland). Images 
were processed with Photoshop 7.0 (Adobe Systems Inc., Munich, Germany). 
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Results 
 
Amniotic fluid derived cells 
Mesenchymal cells from human amniotic fluid (amniocytes) were isolated, 
cultured and passaged several times. Upon 90–100 % confluence, the amniocytes 
(Fig. 1a) demonstrated a rather irregular arrangement as opposed to the one of 
human fibroblasts (Fig. 1b) that appeared to be more ‘‘streamlined’’. The amniocytes 
shared the spindle-shaped morphology with fibroblasts. 
Amniocytes were incorporated into bovine collagen type I hydrogels and FdA 
staining was performed 3 days thereafter to assess the viability of the cells as well as 
their morphology in this 3D culture system. FdA staining revealed high cell viability 
with spindle-shaped, dendrite, or stellate morphology of the cells (Fig. 1c), similar to 
fibroblasts in collagen hydrogel (Fig. 1d). 
 
Macroscopic appearance of epidermis development on transplanted grafts 
At transplantation of the three types of skin substitutes (amniocytes in the 
dermis, fibroblasts in the dermis, or, acellular dermis) on the back of immuno-
incompetent rats, no macroscopic difference between the three types of transplants 
could be observed (Fig. 2a–c). Seven days post transplantation, complete take of all 
grafts in all animals was observed (Fig. 2d–f). The presence or absence of an 
epidermis was difficult to asses macroscopically at this early stage, although the 
transplants with acellular dermis appeared to have a rather moist surface (Fig. 2f), 
usually indicating a missing or poorly developed epidermis. Twenty-one days post 
transplantation, grafts containing Amniocytes or fibroblasts showed a clearly 
epithelialised surface and seemed well integrated into the rat tissue (Fig. 2g, h). 
Grafts with an acellular dermis had a moist surface (Fig. 2i) and appeared smaller 
compared to the other transplants. 
 
Histological analysis of the epidermis 
Excised grafts were sectioned and stained with haematoxylin & eosin. Seven 
days post transplantation, skin substitutes with amniocytes (Fig. 3a) showed a 
stratified epidermis of 4–6 keratinocyte layers with near-normal anatomy and a 
stratum corneum. The dermal part of these grafts was clearly distinguishable from 
the underlying tissue, and evenly distributed cells could be detected in the dermis 
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(Fig. 3a). Similar features were observed in grafts with fibroblasts (Fig. 3b). Twenty-
one days post transplantation, the neodermis in transplants with Amniocytes and with 
fibroblasts showed a higher cell number than 7 days post transplantation and the 
epidermis demonstrated about 6–8 layers on the amniocyte-grafts (Fig. 3c) and 
about 8–10 layers on the fibroblast-grafts (Fig. 3d). Twenty-one days post 
transplantation, a large part of the dermis in grafts with acellular dermis was devoid 
of any cells, and no epidermal elements were detectable (Fig. 3e). 
 
Basal lamina deposition, epidermal homeostasis and proliferation 
Grafts excised 21 days post transplantation were sectioned and 
immunofluorescence stainings were performed. Staining of the amniocyte-grafts with 
an antibody to the basal lamina component laminin 5 (Fig. 4a) demonstrated a 
deposition of a continuous basal lamina in all transplants and keratin 1 expression 
was not fully established in all suprabasal layers (Fig. 4a). In fibroblast-grafts in the 
dermis, laminin 5 staining revealed a continuous basal lamina and keratin 1 was 
expressed in all suprabasal layers (Fig. 4b). In amniocyte-grafts, keratin 16 was 
continuously expressed in all suprabasal layers (Fig. 4c). Amniocyte-grafts 
demonstrated more cells expressing the proliferation marker Ki67 in the basal layer 
(Fig. 4c), while the fibroblast-grafts demonstrated more Ki67 positive cells in the 
dermis (Fig. 4d). In fibroblast-grafts, keratin 16 expression was found in all 
suprabasal layers (Fig. 4d). In amniocytes-grafts, keratin 15 expression could be 
observed in most of the basal cells, whereas expression of keratin 19 was detected 
in most suprabasal cells (Fig. 4e). In fibroblast-grafts, keratin 15 expression was 
found in most basal cells, and a subpopulation of these basal cells was positive for 
keratin 19 (Fig. 4f). 
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Discussion 
 
We describe here the generation of dermo-epidermal skin grafts containing 
human primary amniotic fluid derived cells in the dermis instead of human fibroblasts. 
These tissue-engineered skin substitutes were compared to tissue-engineered 
dermo-epidermal skin substitutes with human primary fibroblasts in the dermis and 
grafts with an acellular dermis. The key finding of our study is that the amniocytes 
can competently substitute for fibroblasts and successfully support epidermis 
stratification and survival. Some aspects deserve detailed consideration. 
The interaction between epithelium and underlying mesenchyme was studied 
extensively for many years. It became clear that for successful epidermal 
stratification and survival, an underlying mesenchyme is absolutely mandatory. The 
mesenchyme provides essential growth factors to the epithelial cells and so 
stimulates the stratification of the epidermis [25–28]. 
It was therefore not surprising that we could not observe epidermis 
stratification, nor survival, in our skin grafts created with an acellular dermis. 
Interestingly, transplants with amniocytes in the dermis showed near-normal 
structure, comparable to control transplants with fibroblasts in the dermis. The 
epithelial cells in amniocyte-grafts stratified to a near-normal epidermis including a 
stratum corneum and deposited a continuous basal lamina. However, expression 
patterns for markers of epidermal homeostasis suggested that 21 days post 
transplantation the epidermis was not yet in a fully homeostatic state. This aspect 
was reinforced by the detection of many suprabasal cells that were positive for 
keratin 19 expression, compared to the fibroblast-grafts where keratin 19 expression 
was restricted to some basal cells. These findings indicate that the development of 
the epidermis within amniocyte containing grafts is basically physiological, but slightly 
slower than in those containing fibroblast. These results provide compelling evidence 
that amniocytes incorporated into the dermal part of a dermo-epidermal skin graft can 
efficiently substitute fibroblasts and correctly support epidermal survival and 
stratification. 
Diagnostic amniocentesis is routinely offered, can be safely performed under 
ultrasound guidance, and is associated with a very low rate of spontaneous abortion 
of only 0.5 % [29]. The removal of an additional small aliquot of amniotic fluid does 
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not represent an additional risk to fetus or mother and also does not apparently 
constitute an ethical concern. 
The present study can be seen as a first step toward tissue engineering of 
fetal skin without the necessity of harvesting a formal fetal skin biopsy. We 
demonstrate that prenatally harvested amniocytes can be successfully employed to 
competently assume the role of dermal fibroblasts in a fetal-postnatal hybrid skin 
substitute (amniocytes = fetal cells, keratinocytes = postnatal cells). Of note, amniotic 
fluid also contains fetal epidermal cells that, hypothetically, might also be harvested, 
isolated, cultured, so as to form a fetal epidermis. Taken together, in a best case 
future scenario, autologous ‘‘fetal skingineering’’ could be accomplished by the sole 
use of amniotic fluid. 
What are then, theoretically, possible applications for such laboratory-grown 
fetal skin? Human fetal surgery for spina bifida is a reality today and represents a 
novel standard of care for select fetuses suffering from that devastating malformation 
[30] (also at our centre [31]). Quite often, the back lesions of these fetal patients are 
very big for successful primary skin closure. In those situations, an ‘‘off-the-shelf’’ 
autologous fetal skin substitute might represent an ideal way to guarantee adequate 
skin coverage. Another hypothetical application might be the use of amniotic fluid 
derived bioengineered fetal skin to treat chronic skin wounds, particularly in 
polymorbid elderly patients which often demonstrate notorious wound healing 
problems. It is in fact conceivable that fetal skin (even if allogenic) harbours more 
wound healing power [8] than postnatal skin substitutes used for the same purpose 
[32, 33]. Finally, one could even think of harvesting and cryopreserving amniotic fluid 
for any potential use later in life. It was in fact shown that stored amniocytes remain 
viable and functional over decades of cryopreservation [10]. If the same holds true for 
amniotic fluid derived epidermal cells, then autologous skin might be engineered at 
any age of the patient for a number of possible indications (giant nevi, burns, scar 
revisions, chronic wounds, and other conditions where larger areas of skin are lost). 
In summary and conclusion, we demonstrate here that amniocytes can 
competently assume the role of dermal fibroblasts in the context of bioengineering a 
full-thickness skin analog. This novel finding has fundamental implications on the 
emerging field of tissue engineering and harbours considerable potential regarding in 
vitro fabrication of both fetal and adult skin. 
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Figures 
 
 
Fig. 1: Comparison of morphology of human primary amniocytes and human primary fibroblasts on 
cell culture plastic (2D) and in a collagen hydrogel (3D). a Phase contrast microscopy of Amniocytes 
shows cell morphology similar to spindle-shape morphology of fibroblasts (b). c Positive fluorescein 
diacetate staining of amniocytes in collagen hydrogel shows dendrite morphology and good viability of 
the cells. d Fluorescein diacetate staining of fibroblasts indicating high viability as seen by the mainly 
dendrite or stellate morphology. Scale bars 40 µm 
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Fig. 2: Macroscopic views of grafts at time point of transplantation (day 0), 7 and 21 days post 
transplantation. a–c Transplants show similar appearance at the day of transplantation. d, e Seven 
days post transplantation, the surface of both amniocyte- and fibroblast-grafts is similar and looks 
rather dull and dry. f Grafts with acellular dermis appear more shiny and moist. g, h Twenty-one days 
post transplantation, grafts with amniocytes and with fibroblasts look similar as shown in d, e. i 
Twenty-one days post transplantation, grafts with acellular dermis look similar as described in f. 
Diameter of the ring (arrow in a) 26 mm (a–i) 
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Fig. 3: Histological evaluation of the excised grafts (haematoxylin & eosin staining). a Seven days 
post transplantation, amniocyte grafts show a correctly stratified epidermis with 4–6 cell layers and a 
stratum corneum. The collagen gel is easily discernable. b Seven days post transplantation, fibroblast-
grafts look similar as described in a. The collagen gel is similar as in a. c Twenty-one days post 
transplantation, the epidermis of amniocyte-grafts is near physiological and has 6–8 cell layers. The 
dermis is markedly populated by cells. d Twenty-one days post transplantation, the epidermis of 
fibroblast grafts is up to 8–10 cell layers thick including stratum corneum, and the dermis is densely 
populated by cells. e Twenty-one days post transplantation, grafts with acellular dermis show neither 
epidermis nor single epidermal cells. The collagen gel is easily detectable and a large part of it does 
not contain cells. The dotted line indicates the border between graft and underlying tissue. Arrows 
point at stratum corneum. cg Collagen gel. Scale bars 100 µm (a–e) 
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Fig. 4: Immunofluorescence stainings of grafts with amniocytes or with fibroblasts in the dermis 21 
days after transplantation. a, b Staining of the basement membrane component laminin 5 (red) reveals 
the deposition of a continuous basement membrane in both types of transplants. Expression of keratin 
1 (green) is not fully established in all suprabasal layers in amniocyte grafts, whereas in fibroblast 
grafts, all suprabasal layers express keratin 1. c, d In both types of transplants, keratin 16 (red) is 
expressed in all suprabasal layers. Proliferation as indicated by expression of Ki67 (green) in the basal 
cell layer of amniocyte-grafts is more pronounced compared to fibroblast-grafts. Proliferation of cells in 
the dermal part is lower in amniocyte-grafts than in fibroblast-grafts. e, f In amniocyte-grafts, keratin 19 
(red) expression is detected in most suprabasal cells, whereas in fibroblast-grafts keratin 19 
expression is restricted to some basal cells. In both types of grafts, keratin 15 expression (green) is 
detected in some basal cells. Scale bars 50 µm 
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4.3 A new model for preclinical testing of dermal substitutes for 
human skin reconstruction 
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Abstract 
 
Background/Purpose Currently, acellular dermal substitutes used for skin 
reconstruction are usually covered with split-thickness skin grafts.  
The goal of this study was to develop an animal model in which such dermal 
substitutes can be tested under standardized conditions using a bioengineered 
dermo-epidermal skin graft for coverage. 
Methods Bioengineered grafts consisting of collagen type I hydrogels with 
incorporated human fibroblasts and human keratinocytes seeded on these gels were 
produced. Two different dermal substitutes, namely Matriderm®, and an acellular 
collagen type I hydrogel, were applied onto full-thickness skin wounds created on the 
back of immuno-incompetent rats. As control, no dermal substitute was used. As 
coverage for the dermal substitutes either the bioengineered grafts were used, or, as 
controls, human split-thickness skin or neonatal rat epidermis were used. Grafts were 
excised 21 days post transplantation. Histology and immunofluorescence was 
performed to investigate survival, epidermis formation, and vascularization of the 
grafts. 
Results The bioengineered grafts survived on all tested dermal substitutes. 
Epidermis formation and vascularization were comparable to the controls. 
 Conclusion We could successfully use human bioengineered grafts to test 
different dermal substitutes. This novel model can be used to investigate newly 
designed dermal substitutes in detail and in a standardized way. 
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Introduction 
 
The today’s gold standard to treat full-skin defects such as burns, giant nevi, 
or avulsion injuries is the transplantation of autologous split-thickness skin [1, 2]. 
Split-thickness skin can be applied directly on the wound bed, or it can be 
transplanted onto different acellular dermal substitutes such as Integra® (Integra) [1, 
3-7] or Matriderm® (Matriderm) [8-13]. Dermal substitutes improve wound healing, 
impede scar contraction, and the cosmetic outcome compared to transplanted split-
thickness skin alone [1, 14, 15]. A newly designed dermal substitute needs to be 
tested pre-clinically for its biological behavior and compatibility with split-thickness 
skin. For most dermal substitutes, tests are performed in a pig animal model with 
porcine split-thickness skin [16-19]. 
The aim of this experimental study was to test whether a human 
bioengineered skin graft can be used to replace human split-thickness skin for the 
pre-clinical testing of acellular dermal substitutes used for skin reconstruction. 
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Materials and Methods 
 
Cell isolation and culture 
Human skin samples were obtained after informed consent from patients 
and/or parents; all described studies were approved by the Medical Ethical 
Committee of the Kanton Zurich. Human primary fibroblasts and keratinocytes were 
isolated as previously described [20].  
 
Engineered dermal substitutes (acellular collagen hydrogels) 
To engineer acellular dermal substitutes, a solution of bovine collagen type I 
was neutralized with a NaOH containing buffer [21] and poured into cell culture 
inserts with a pore size of 3 µm (BD Falcon, Basel, Switzerland). After incubation for 
2h at 37°C, the acellular dermal substitutes were plastically compressed as 
previously described [22]. The acellular collagen hydrogels were incubated for five 
days in Rheinwald and Green medium (RGM) [20], before transplantation, with 
medium changes performed every 2-3 days. 
 
Matriderm 
 Matriderm 1 mm (Dr. Suwelack Skin & Health Care AG, Billerbeck, Germany) 
was cut into round pieces of 26 mm diameter and incubated in RGM for three 
minutes immediately before transplantation. 
 
Human bioengineered skin grafts (bioengineered grafts) 
Human bioengineered skin grafts based on collagen type I hydrogels with 
incorporated human dermal fibroblasts and human keratinocytes seeded on these 
hydrogels were created as previously described [23]. Briefly, 105 human primary 
dermal fibroblasts were mixed with bovine collagen type I (BD Biosciences, Basel, 
Switzerland) and neutralized with a buffer containing NaOH. The solution was poured 
into cell culture inserts with a pore size of 3 µm (BD Falcon, Basel, Switzerland). 
After incubation of 2h at 37°C and 5% CO2, the hydrogels were plastically 
compressed [22]. The hydrogels were cultivated in DMEM supplemented with 10% 
FCS, and media changes were performed every 2-3 days. 7.5x105 human primary 
keratinocytes were seeded onto the complete surface of the hydrogels five days 
thereafter. After three days of submerged cultivation in RGM, hydrogels were 
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cultivated for additional three days at the air-liquid interface, before transplantation 
onto immuno-incompetent rats. 
 
Human split-thickness skin 
 Human split-thickness skin (leftovers from split-thickness skin transplantations) 
was received from patients from the University Children’s Hospital Zurich after 
informed consent from patients and/or parents. Split-thickness skin was stored in 
DMEM at 4 °C until transplantation. 
 
Neonatal rat epidermis 
Neonatal rat epidermis of appropriate size was obtained from full-thickness 
skin samples from newborn Wistar rats (University of Zurich animal breeding 
program). Full-thickness skin samples were treated overnight in dispase (BD 
Biosciences) diluted 1:1 in Hank’s balanced salt solution (Invitrogen) containing 5 
mg/ml gentamicin (Invitrogen) at 4 ºC. To obtain an epidermis free of dermal 
components, the epidermis was peeled off the dermis immediately before 
transplantation. 
 
Transplantation  
 All animal experiments were approved by the local Committee for 
Experimental Animal Research. The preparation of immuno-incompetent nu/nu rats 
(age 8-10 weeks, Harlan, Horst, The Netherlands) was performed as previously 
described [24]. Steel rings with a diameter for 26 mm were implanted into full-
thickness skin defects on the back of the rats to prevent wound closure by ingrowth 
of rat skin into the wound area. Two different dermal substitutes, namely Matriderm 
and engineered acellular collagen hydrogels, were placed onto the wounds. The 
dermal substitutes were immediately covered with a) human bioengineered graft, b) 
human split-thickness skin, or, c) neonatal rat epidermis. Controls were performed 
without any dermal substitute, where the coverage grafts were transplanted directly 
on the fascia (Fig. 1). Sample sizes for each group are summarized in table 1. 
Transplants were covered with a silicon foil (Silon-SES, BMS, Allentown, PA, USA). 
Once a week, wound dressing changes and photographic documentations were 
performed. Animals were sacrificed 21 days post transplantation. Grafts were 
excised, halved, and embedded in O.C.T compound (Tissue-Tek®, Sakura Finetek, 
RESULTS – PUBLICATION III 
96 
Japan) or fixed in 4% paraformaldehyde (Medite Medizintechnik AG, Nunningen, 
Switzerland) and then embedded in paraffin (McCormick, Richmond, USA). 
 
Histology 
 For haematoxylin & eosin staining, 10 µm thick paraffin sections were cut and 
stainings were imaged by light microscopy (Nikon Eclipse TE2000-U inverted 
microscope connected with a DXM1200F digital camera (Nikon AG, Egg, 
Switzerland). 
 For immunofluorescence stainings, O.C.T embedded tissue was frozen at -20 
°C, and sectioned at 10 µm. Permeabilisation was performed in ice-cold acetone for 
5 minutes, thereafter sections were air-dried, and washed three times in phosphate 
buffered saline (PBS). After blocking with PBS containing 2% bovine serum albumin 
(Sigma, Buchs, Switzerland) for 30 minutes at room temperature, sections were 
incubated with the pre-labeled antibodies for 1 hour at room temperature. Sections 
were washed three times with PBS, then nuclei were stained with 1 µg/ml Hoechst 
33341 (Sigma, Buchs, Switzerland) in PBS for 5 minutes at room temperature. 
Sections were washed two times with PBS, and finally mounted with Dako 
fluorescent mounting solution (Dako, Baar, Switzerland). 
 
Antibodies 
The following antibodies were used: K1 (clone LHK1, 1:200, Novus 
Biologicals, Littleton, USA); Lam5α3 (clone P3H9-2, 1:100, Santa Cruz, Labforce AG, 
Nunningen, Switzerland); CD31 (clone TDL-3A12, 1:50, BD Biosciences 
Pharmingen, Basel, Switzerland) ; CD90 (clone AS02, 1:100, Dianova, Hamburg, 
Germany). 
For immunofluorescence stainings, primary antibodies were pre-labeled with 
either Alexa488 or Alexa555 conjugated polyclonal goat F(ab’)2 fragments, according 
to the manufacturer’s instructions (Zenon Mouse IgG Labelling Kit, Molecular Probes, 
Invitrogen, Basel, Switzerland). 
 
Fluorescence microscopy 
The immunofluorescence stainings were analyzed with a Nikon Eclipse 
TE2000-U inverted microscope, equipped with Hoechst, FITC and TRICT filter sets 
and connected with a DXM1200F digital camera (Nikon AG, Egg, Switzerland). 
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Results 
 
Macroscopic appearance of epidermis on transplanted grafts 
 Immediate after transplantation, the human bioengineered grafts 
macroscopically appeared similar in all groups (transplanted either directly on the 
fascia, on Matriderm, or, on an engineered acellular collagen hydrogel) (Fig. 2a-c). At 
time point of transplantation, human split-thickness skin macroscopically looked 
similar in all three groups, the underlying dermal substitute was not visible through 
the split-thickness skin (Fig. 2d-e). At time point of transplantation, neonatal rat 
epidermis appeared very thin and transparent (Fig. 2g-i) and the underlying dermal 
substitute was visible. Matriderm seemed red and dull, as a result from its incubation 
in RGM prior to transplantation (Fig. 2h). The engineered acellular collagen hydrogel 
shined white through the neonatal rat epidermis (Fig. 2i). 
21 days post transplantation, a complete take of the bioengineered grafts in all 
three groups was observed (Fig. 3a-c). Grafts showed an epithelialised surface and 
seemed well integrated into the rat tissue. 21 days post transplantation, the split-
thickness skins seemed well integrated into the rat tissue and in all three groups 
good take was observed with epidermis covering the complete surface (Fig. 3d-f). 21 
days post transplantation, neonatal rat epidermis transplanted directly onto the fascia 
(Fig. 3g) macroscopically showed a better take rate compared to neonatal rat 
epidermis transplanted on Matriderm (Fig. 3h) and on engineered acellular collagen 
gel (Fig. 3i). 
 
Histological analysis of grafts excised 21 days post transplantation 
 Grafts excised 21 days post transplantation were sectioned and stained with 
haematoxylin & eosin. Human bioengineered grafts showed a stratified epidermis of 
6-9 layers that was similar in all three groups (Fig. 4a-c). Remnants of Matriderm 
could be detected between the bioengineered graft and the underlying rat tissue (Fig. 
4b). The bioengineered graft could be distinguished from the engineered acellular 
collagen hydrogel, which was partially populated by rat cells (Fig. 4c). 
 Human split-thickness skin showed similar appearance in all three groups, 
with a multi-layered epidermis, prominent rete ridges, and a very prominent stratum 
corneum (Fig. 4d-f). 
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 Transplantation of neonatal rat epidermis was partially successful when 
transplanted directly on the fascia, where a 2-3 layered epidermis could be detected 
(Fig. 4g). When transplanted on Matriderm (Fig. 4h) or on engineered acellular 
collagen gel (Fig. 4i), the epidermis did not survive, and only some single epidermal 
cells could be detected. The Matriderm material could not be clearly distinguished 
from the underlying rat tissue (Fig. 4h). The engineered acellular collagen hydrogel 
was clearly detectable and was only partially colonized by ingrown rat cells (Fig. 4i). 
 
Basal lamina deposition and epidermis stratification 
 Grafts excised 21 days post transplantation were sectioned and 
immunofluorescence stainings were performed. Staining with an antibody to the 
basal lamina component laminin 5 revealed the deposition of a continuous basal 
lamina in human bioengineered grafts in all three groups (Fig. 5a-c). In 
bioengineered grafts, all suprabasal keratinocyte layers expressed keratin 1 (Fig. 5a-
c). Similar expression patterns for laminin 5 and keratin 1 were observed in 
transplanted human split-thickness skin in all three groups (Fig. 5d-f). In the 
specimens where neonatal rat epidermis was transplanted, neither basal lamina 
deposition nor keratin 1 expression was detected in either group (Fig. 5g-i). 
 In human bioengineered grafts, the ingrowth of rat blood vessels, as detected 
by staining with CD31, was similar in all three groups (Fig. 6a-c). The human 
fibroblasts of the bioengineered graft could be detected by staining with CD90 in all 
groups (Fig. 6a-c). Similarly, in specimens covered with human split-thickness skin, 
rat blood vessels were found in proximity to the epidermis (Fig. 6d-f). The human 
origin was confirmed by CD90 staining, which was expressed by human fibroblasts in 
the split-thickness skin (Fig. 6d-f). In specimens covered with neonatal rat epidermis, 
the ingrowth of rat blood vessels was similar in all three groups (Fig. 6g-i). No human 
fibroblasts expressing CD90 were detected (Fig. 6d-i). 
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Discussion 
 
The goal of this experimental study was to test whether a human 
bioengineered skin graft can be used to replace human split-thickness skin for the 
pre-clinical testing of acellular dermal substitutes used for skin reconstruction. These 
bioengineered grafts were compared to the current standard coverage of dermal 
substitutes, i.e. split-thickness skin, and to neonatal rat epidermis. In the global 
picture, human bioengineered grafts demonstrated a very similar biological behavior 
as split-thickness skin, while neonatal rat epidermis performed significantly poorer. 
 Several points deserve a detailed comment: Split-thickness skin was used as 
positive control for the new model, as split-thickness skin transplantation is the gold 
standard for complex dermo-epidermal skin reconstruction in clinical practice since 
more than 10 years [1, 25, 26]. Interestingly, we found that the human bioengineered 
graft behaved as well as split-thickness skin. When transplanted on Matriderm as 
well as on engineered acellular collagen hydrogel, the bioengineered skin grafts 
show similar biological performance as seen with transplantation of split-thickness 
skin. A continuous basal lamina was deposited as evidenced by staining for the basal 
lamina component laminin 5, and all suprabasal cells expressed keratin 1 as is seen 
in normal homeostatic skin. Rat blood vessels grew into the dermal part of the 
bioengineered grafts and so ensured sufficient oxygen and nutrient supply for the 
epidermis. The presence of human fibroblasts, which are indispensable key players 
regarding skin architecture and functionality, in the bioengineered skin grafts could 
be confirmed by the detection of human CD90-specific cells. 
In sharp contrast, the performance of neonatal rat epidermis alone was 
significantly poorer. The most tenable explanation for the good performance of the 
bioengineered graft and split-thickness skin as opposed to rat epidermis is the 
presence of dermal components in the former and a complete lack of those elements 
in the latter. It is well documented in the literature that viable and functional dermal 
elements are crucial for epidermal viability and functionality [27-31]. 
The almost identical biological behavior of the bioengineered grafts compared 
to split-thickness skin indicates that human bioengineered grafts might be used in the 
future instead of split-thickness skin as standard dermo-epidermal coverage to test 
any newly designed dermal substitutes. Of note, human bioengineered grafts can be 
prepared in a very standardized way in terms of cell numbers, cell types, and 
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thickness of the graft. The use of a humanized model represents an additional 
advantage, given the fact that the mentioned preclinical testing procedures may lead 
to applications in human patients. 
 In summary and conclusion, this series of experiments provides evidence that 
human bioengineered skin grafts can successfully be employed to test different 
acellular dermal substitutes designed for skin reconstruction. Such testing is 
indispensable before new products can be applied clinically. 
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Table 1: Summary of the sample sizes for each group. 
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Fig. 1 Schematic overview on the different combinations of dermal substitutes and coverage used in 
this study. a-c Human bioengineered graft transplanted onto the fascia (a), on Matriderm (b), or, on 
engineered acellular collagen hydrogel (c). d-f Human split-thickness skin transplanted onto the fascia 
(d), on Matriderm (e), or, on engineered acellular collagen hydrogel (f). g-i Neonatal rat epidermis 
transplanted onto the fascia (g), on Matriderm (h), or, on engineered acellular collagen hydrogel (i). 
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Fig. 2 Macroscopic view of grafts at time point of transplantation. a-c Human bioengineered graft 
appearance is similar in all three groups. The underlying engineered acellular collagen hydrogel is 
detectable in c (arrow). d-f Human split-thickness skin shows similar appearance in all three groups. 
g-h Neonatal rat epidermis looks similar when transplanted onto fascia and Matriderm. i Neonatal rat 
epidermis looks pale when transplanted onto engineered acellular collagen hydrogels. Diameter of the 
ring (arrow in a) 26 mm (a-i) 
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Fig. 3 Macroscopic view of grafts 21 days post transplantation. a-c Human bioengineered grafts show 
complete take in all three groups. Grafts look almost identical in all three groups. d-f Human split-
thickness skin show complete take in all three groups. Grafts look almost identical in all three groups. 
g-i Neonatal rat epidermis show only partial take that is similar in all three groups. The surviving 
epidermal islets look very fragile and do not seem to be firmly attached to the wound bed. 
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Fig. 4 Histological evaluation of grafts (haematoxylin & eosin staining) excised 21 days post 
transplantation. a Human bioengineered grafts transplanted onto the fascia show 6-9 keratinocyte 
layers and the dermal part of the bioengineered graft can be clearly distinguished from the underlying 
tissue (cg = collagen gel). b Human bioengineered grafts transplanted on Matriderm show similar 
appearance as in a. Remnants of Matriderm are detectable between the bioengineered graft and the 
underlying rat tissue (M = Matriderm). c Human bioengineered grafts transplanted on acellular 
collagen show similar appearance as in a. The border between graft and engineered acellular collagen 
hydrogel can be discerned (dotted line). d-f Human split-thickness skin look similar in all three groups. 
The normally configured epidermis shows a stratum corneum (arrows) and rete ridges (arrow heads). 
g Neonatal rat epidermis transplanted onto the fascia is very thin and unstratified (black line). h 
Neonatal rat epidermis transplanted onto Matriderm does not survive, no epidermis is detectable. i 
Neonatal rat epidermis transplanted on engineered acellular collagen hydrogel does not survive, only 
single epidermal cells are occasionally detectable. The collagen gel is easily discernable and there are 
almost no cells. (acg = engineered acellular collagen hydrogel). Scale bars 100 µm (a-i). 
 
 
RESULTS – PUBLICATION III 
 107 
 
Fig. 5 Immunofluorescence stainings (laminin 5 and keratin 1) of grafts excised 21 days post transplantation. a-c 
In human bioengineered grafts in all three groups, staining of the basement membrane component laminin 5 (red) 
reveals the deposition of a continuous basement membrane. In all three groups, all suprabasal cells express 
keratin 1 (green). d-f Human split-thickness skin in all three groups shows similar expression of laminin 5 (red) 
and keratin 1 (green) as described for a-c. g-i In all three groups with neonatal rat epidermis transplantation, there 
is no laminin 5 (red) nor keratin 1  (green) expression. Scale bars 50 µm. 
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Fig. 6 Immunofluorescence stainings (CD31 and CD90) of grafts excised 21 days post transplantation. 
a-c In human bioengineered grafts in all three groups, staining with CD31 (red) reveals the ingrowth of 
rat blood vessels into the dermal part of the coverage graft. Also, human fibroblasts expressing CD90 
(green) are detected in all groups. d-f In human split-thickness skin, rat blood vessels grew into the 
dermal part as detected by CD31 staining (red). Human fibroblasts are detected by staining with CD90 
(green). g-i In neonatal rat epidermis in all three groups, staining with CD31 (red) reveals the ingrowth 
of rat blood vessels into the transplants. In all three groups, no human fibroblasts expressing CD90 
(green) are detected. Scale bars 50 µm. 
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4.4 Skingineering I: engineering porcine dermo-epidermal skin 
analogues for autologous transplantation in a large animal model 
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Abstract 
 
Background Extended full thickness skin defects still represent a 
considerable therapeutic challenge as ideal strategies for definitive autologous 
coverage are still not available. Tissue engineering of whole skin represents an 
equally attractive and ambitious novel approach. We have recently shown that 
laboratory-grown human skin analogues with near normal skin anatomy can be 
successfully transplanted on immuno-incompetent rats. The goal of the present study 
was to engineer autologous porcine skin grafts for transplantation in a large animal 
model (pig study = intended preclinical study). Materials and methods Skin biopsies 
were taken from the pig’s abdomen. Epidermal keratinocytes and dermal fibroblasts 
were isolated and then expanded on culture dishes. Subsequently, highly 
concentrated collagen hydrogels and collagen/fibrin hydrogels respectively, both 
containing dermal fibroblasts, were prepared. Fibroblast survival, proliferation, and 
morphology were monitored using fluorescent labelling and laser scanning confocal 
microscopy. Finally, keratinocytes were seeded onto this dermal construct and 
allowed to proliferate. The resulting in vitro generated porcine skin substitutes were 
analysed by H&E staining and immunofluorescence. 
Results Dermal fibroblast proliferation and survival in pure collagen 
hydrogels was poor. Also, the cells were mainly round-shaped and they did not 
develop 3D networks. In collagen/fibrin hydrogels, dermal fibroblast survival was 
significantly higher. The cells proliferated well, were spindle-shaped, and formed 3D-
networks. When these latter dermal constructs were seeded with keratinocytes, a 
multilayered and partly stratified epidermis readily developed. 
Conclusion This study provides compelling evidence that pig cell-derived 
skin analogues with near normal skin anatomy can be engineered in vitro. These 
tissue-engineered skin substitutes are needed to develop a large animal model to 
establish standardized autologous transplantation procedures for those studies that 
must be conducted before ‘‘skingineering’’ can eventually be clinically applied. 
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Introduction 
 
Large full thickness skin defects typically result from burns, massive avulsion 
injuries, septic skin necroses, or from extended excision of scars or nevi [1–10]. The 
coverage of such lesions still poses a very significant challenge: the functionally and 
cosmetically best therapeutic option is transplanting full thickness autologous skin, 
however, donor sites are limited in a prohibitive way when there is extensive demand 
[11–14]. On the other end of the therapeutical spectrum stands the almost unlimited 
supply of cultured autologous epithelial autografts (CEA) (in numerous variations) 
that, despite enormous basic science and clinical research efforts, still requires 2–3 
weeks of cultivation time and still yields far from ideal results [15–23]. 
Clearly, the clinical introduction of nowadays widely used dermal regeneration 
templates (e.g. Integra DRT® and Matriderm®) and the development of more 
sophisticated laboratory-grown skin substitutes containing keratinocytes, fibroblasts, 
extracellular matrix components, growth factors, and other cytokines have pushed 
the frontiers further [8, 16, 17, 24–29]. 
Yet, these techniques are still plagued with considerable problems including 
intricate and time consuming laboratory processes, fragility of grafts, staged 
operative procedures, susceptibility to infection, poor graft take, and, finally and most 
importantly, not really satisfactory long term results in terms of both functionality and 
cosmetic appearance of the reconstituted skin [30–32]. 
We have, therefore, invested over 10 years of laboratory research into the 
ambitious project of engineering an anatomically near normal skin analogue. Briefly 
summarized, we have managed to grow a hydrogel-based dermo-epidermal 
construct featuring a correctly stratified epidermis, a basement membrane, the 
characteristic structures of the dermo-epidermal junction, and a close to normal, 
prevascularised dermis [33]. These grafts, cultured from human cells, were then 
successfully grafted onto immuno-incompetent rats [34–36]. 
Theoretically, this progress may be seen as the indispensable evidence 
required before an eventual clinical application in human patients can be envisioned. 
Practically, however, we are facing the problem that the above mentioned human 
tissue grafts used in our rat model are way too small and ill-configured (round grafts, 
2.5 cm diameter, covering about 4 cm2) when looking at grafts suitable for large scale 
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transplantation in human patients. Ideally, such transplants should be rectangular 
and large (covering 50–100 cm2). 
Consequently, we have embarked on culturing skin substitutes with near 
normal anatomical architecture, mechanical properties allowing standard surgical 
handling, and appropriate size matching the prerequisites for large scale autologous 
transplantation in a large animal model (=immunocompetent setting). This article 
describes in vitro engineering of such grafts to be later used in pigs. 
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Materials and methods 
 
In view of the envisioned animal model for large scale autologous 
transplantation, we have chosen the pig (Schweizer Edelschwein). Biopsies were 
taken as outlined in detail in the companion paper published in the same issue 
(Skingineering II). 
 
Isolation and culture of keratinocytes and fibroblasts 
Porcine skin samples (3x1 cm) were cut to 2–3 mm2pieces and incubated for 
15-18 h at 4°C in 12 U/ml dispase in HBSS containing 5 µg/ml gentamycin. The 
epidermis was then separated from the dermis using forceps. Epidermal cells were 
isolated by incubation in1% trypsin, 5 mM EDTA for 3 min at 37°C. After 
centrifugation, the cell pellet was resuspended in CT57keratinocyte medium 
containing 5 µg/ml gentamycin (CELLnTEC Advanced Cell Systems AG, Bern, 
Switzerland), then seeded on collagen type I-coated cell culture dishes (BD Falcon, 
Basel, Switzerland). Medium was changed every 2–3 days. 
The dermal tissue was digested in 2 mg/ml Collagenase for about 60 min at 
37°C. Isolated cells were seeded on 10 cm cell culture dishes containing fibroblast 
growth medium (DMEM supplemented with 10% FCS, 4 mM alanyl-L-glutamine, 1 
mM sodium pyruvate, and 5 µg/ml gentamycin) and allowed to attach overnight, 
before dead cells and erythrocytes were removed by three washes in phosphate 
buffered saline (PBS). Collagenase was from Sigma (Buchs, Switzerland), and all 
other compounds were from Invitrogen (Basel, Switzerland). 
 
Organotypic skin cultures 
Organotypic cultures were prepared using a previously established transwell 
system (4.2 cm26-well cell culture inserts with membranes of 3.0 µm pore-size, BD 
Falcon, Basel, Switzerland). A highly concentrated acidic solution of bovine collagen 
type I (5 mg/ml, Symatese Biomatériaux, 69630 Chaponost, France) was neutralized 
on ice by drop wise addition of 0.5 M NaOH and immediately mixed with 5x104human 
primary dermal fibroblasts (passage 1–2) suspended in fibroblast growth medium. 
For the fibrin-containing preparations, fibrinogen was added to the collagen before 
neutralization, thrombin was added after neutralization, and mixed thoroughly. All 
components were chilled on ice during gel preparation. The mixture was transferred 
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into 6-well culture inserts immediately and allowed to gel for 10 min at room 
temperature before being transferred into a cell culture incubator. 
The fibroblast-containing gels were grown in fibroblast growth medium for 3–7 
days before 7.5x105keratinocytes were seeded onto the entire surface of each gel. 
After initial submersed cultivation in Rheinwald and Green keratinocyte differentiation 
medium (RGM) [37] for 3–7 days, the medium level was lowered to 1.5 ml to expose 
the developing epidermis to air (air–liquid interface) for additional 7–10 days. Medium 
changes were performed every 2–3 days. 
 
Fluorescein diacetate (FdA) vital cell staining 
Fluorescein diacetate (FdA) staining was performed as published and proven 
to be suitable for the determination of cell viability in tissue-engineered skin [38, 39]. 
In short, cell culture medium was replaced for 2 min with the equal volume of 5 µM 
FdA in PBS, freshly prepared from a stock solution of 5 mM FdA in acetone. The FdA 
was removed by washing twice in PBS before fresh culture medium was applied. 
 
Actin and nuclear staining 
Gels were fixed in 4% paraformaldehyde and permeabilised in 
acetone/methanol (1:1) for 20 min at -20°C, air dried, and washed 3x in PBS. Then 
they were blocked in PBS containing 2% BSA (Sigma) for 30 min. Cytoskeletal actin 
was stained with phalloidin-TRITC in blocking buffer for 1 h at room temperature. 
Slides were washed twice for 5 min in PBS. Thereafter sections were incubated for 5 
min in PBS containing 1 mg/ml Hoechst 33342 (Sigma) and then washed twice for 5 
min in PBS. Finally, the samples were mounted with Dako fluorescent mounting 
solution (Dako, Baar, Switzerland). 
 
Fluorescence microscopy 
Fluorescence microscopy pictures were photographed using a DXM1200F 
digital camera connected to a Nikon Eclipse TE2000-U inverted microscope, 
equipped with Hoechst 33342, FITC, and TRITC filter sets or Nikon SMZ1500 stereo 
microscope with FITC filters (Nikon AG, Egg, Switzerland), (Software: Nikon ACT-1 
vers. 2.70). 
For confocal imaging, a Nikon C1 Laser Scanning Microscope upgrade on the 
Eclipse TE2000-U was used. A helium–neon laser with 543-nm excitation was used 
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for tetramethylrhodamineiso-thiocyanate (TRITC) and 408- nm excitation was used 
for Hoechst 33342. With the Plan Apo 40 c/N.A.0.95 objective 50 optical sections 
were captured. Images were processed with Imaris 6.4.0 (Bitplane, Zurich, 
Switzerland) and Photoshop 7.0 (Adobe Systems Inc, Munich, Germany). 
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Results 
 
Cell isolation 
Porcine dermal fibroblasts could be isolated efficiently from the dermis 
according to the protocol and media established for the isolation of human dermal 
fibroblasts [35]. Starting from a 3x1 cm skin biopsy, we received approximately one 
million fibroblasts within 2–3 days that could be further expanded and passaged. This 
efficiency as well as proliferation rate is comparable to that of human fibroblasts. 
Importantly, the morphology of porcine fibroblasts was typical and similar to human 
fibroblasts (Fig. 1a) [40]. Most cells were viable as shown by viability assay using 
FdA (Fig. 1b). 
Trypsinisation of the porcine epidermis resulted in rapid release of 
keratinocytes that attached within 2 h to bovine collagen type I-coated cell culture 
dishes. Within 5–8 days the keratinocytes could be expanded to six million cells in a 
medium optimised for human keratinocyte precursor enrichment. The morphology of 
confluent keratinocytes resembled the typical cobblestone pattern of epithelial cells 
with some interspersed large cells (Fig. 1c). By staining with FdA we could show that 
the majority of cells were vital (Fig. 1d). Therefore our procedure used for human skin 
cell isolation and cultivation could be applied for porcine cells without any changes 
[35]. 
 
Fibroblast behaviour in collagen 
When porcine fibroblasts were cultivated in highly concentrated collagen type I 
hydrogels (3 mg/ml), FdA staining revealed that only few vital cells were present 2 
days after gel preparation. Furthermore, the majority of cells were round and did not 
show dendritic or stellate morphology typical for human fibroblasts in collagen gels 
and in normal dermis [40]. After prolonged cultivation in collagen gels (10 days), 
some porcine fibroblasts started to proliferate and acquired stellate morphology (data 
not shown). Porcine fibroblasts seeded in fibrin gels however, were fastly proliferating 
and showed dendritic or stellate morphology already 1 day after gel preparation (data 
not shown). We therefore included increasing fibrin concentrations from 0.2 to 1.0 
mg/ml in collagen gels to stimulate porcine fibroblasts. Confocal scanning laser 
microscopy of actin-stained fibroblasts showed a clear effect of fibrin on cell density 
and morphology. Already 3 days after gel preparation, this effect was detectable and 
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it intensified over the ensuing days. As little as 0.2 mg/ml fibrin in collagen increased 
the number of vital cells with mainly stellate or dendritic morphology (Fig. 2a, b). This 
effect was slightly more pronounced with 0.5 and 1.0 mg/ml fibrin (Fig. 2c, d). 
 
Porcine in vitro skin model 
Already one day after seeding porcine keratinocytes on the fibroblast 
containing gels, a confluent keratinocyte layer was established, indicating that 
porcine keratinocytes can attach and survive on collagen gels (data not shown). This 
keratinocyte layer was stable during the initial submersed cultivation phase. During 
the following air-exposed cultivation phase, a partly stratified epidermis developed 
(Fig. 3a): a distinct basal layer, 5–7 suprabasal layers, and a well developed stratum 
corneum (conjunctum and disjunctum) were present. Notably, a stratum granulosum 
and spinosum could not be distinguished morphologically at this stage. Also, the 
dermo-epidermal junction was not yet fully established, resulting in an apparently 
accidental separation of epidermis and dermis in histological sections (cutting 
artefact). Fibroblasts were present within the dermal component (Fig. 3b). In 
summary, these features of the engineered porcine skin were typical for in vitro 
generated skin at early stages that will develop further after transplantation [35]. 
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Discussion 
 
This is the first report on in vitro engineering of a pig cell derived skin analogue 
consisting of a multilayered epidermis, a preformed dermo-epidermal junction, and a 
collagen gel-based dermis-like structure containing fibroblasts and essential 
extracellular matrix components. In other words, the desirable basic graft profile is 
basically matched. The following crucial aspects deserve a detailed comment. 
First, and most importantly, the graft does exhibit the most essential 
anatomical hallmarks of skin, although not fully developed. For instance, the 
epidermis is not yet normally stratified and differentiated. Also, the dermo-epidermal 
junction is still weak in that cutting for histology easily leads to disruption between 
epidermis and dermis which is not the case in normal skin. Similarly, the dermal 
compartment of the construct is, in reality, to be seen as a competent template for 
the later establishment of a mature dermis. Although abundant dermal fibroblasts, 
viewed as the key effector cells of the dermis [41], are present, and although certain 
crucial ECM components are part of the template, the physiological inventory of 
components and spatial arrangement of these is not yet accomplished. Moreover, 
certain morphologic characteristics like rete ridges and dermal vasculature are 
absent at this stage. Obviously, skin appendages are absent. 
This ‘‘set of imperfections’’ is mostly identical to what we found when 
engineering small human cell-derived skin analogues [34, 35]. Interestingly, after 
transplantation onto immuno-incompetent rats, we observed maturation and 
differentiation processes finally leading to a near normal skin anatomy (apart from 
missing skin appendages) [34, 35]. It is, therefore, reasonable to assume that similar 
mechanisms will also take place after autologous transplantation of the described 
grafts in the pig model. 
Second, since the planned transplantation of the skin substitutes described 
here in a pig model is intended to be the last preclinical evaluation, it is imperative 
that all laboratory procedures (cell isolation, expansion, and Organotypic culture 
system) should be identical or at least very similar to our already established human 
cell-based system [34, 35]. This is in fact the case for most aspects. In particular, we 
used the identical cell isolation technique as well as media and growth conditions as 
we did for our human cell-derived experiments [34, 35]. The only initial lack of 
correspondence was that porcine fibroblasts did not develop as well in highly 
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concentrated collagen gels as human fibroblasts did. By addition of fibrin, however, 
this problem could be solved effectively in that porcine fibroblasts were stimulated to 
behave like human fibroblasts. This observation is interesting in two ways. It raises 
the questions why porcine fibroblasts do not tolerate high collagen concentrations 
and whether the already favourable growth conditions for human fibroblasts could be 
further improved by adding fibrin to the collagen matrix. 
In summary, this study shows that pig cell-derived skin analogues closely 
approaching normal skin anatomy can be engineered in vitro. Evidently, the next 
experimental step is the development of an appropriate pig model in order to 
establish a standardized transplantation procedure for further studies. 
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Figures 
 
 
Fig. 1: Two-dimensional cell culture of primary porcine fibroblasts and keratinocytes. a Phase contrast 
microscopy shows typical spindle like morphology of fibroblasts in two-dimensional culture. b Positive 
FdA labelling indicates the viability of all adherent fibroblasts. c The majority of confluent porcine 
primary keratinocytes display typical epithelial cobblestone morphology, while few cells are 
significantly larger and round. d FdA staining reveals that both, the large and the small keratinocytes, 
are vital. Scale bars 50 µm (a + b); 100 µm (c + d)] 
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Fig. 2: Laser scanning confocal microscopy of porcine fibroblasts in three-dimensional collagen gels, 
7 days after preparation. Actin cytoskeleton staining (red) and nuclear staining (blue).a In highly 
concentrated collagen gels, only few porcine fibroblasts survive and most cells are round or have few 
extensions. b–d By adding increasing fibrin concentrations, more fibroblasts are present and the 
prevailing morphology is stellate or dendritic. Fibrin concentrations were (b) 0.2 mg/ml, (c) 0.5 mg/ml, 
(d) 1.0 mg/ml. (scale bars 50 µm, grids 20 µm) 
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Fig. 3: Histological evaluation of in vitro engineered porcine skin, 20 days in culture, H&E staining. a A 
partly stratified epidermis with a well defined stratum corneum (sc), 5–7 suprabasal layers (sl), and a 
dense stratum basale (sb) have developed on the dermal equivalent (de). Of note, the junction 
between epidermis and dermis is still weak and disrupted when preparing sections. b Fibroblasts were 
present within the dermal component (gel). (scale bars 50 µm) 
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4.5 Skingineering II: transplantation of large-scale laboratory-grown 
skin analogues in a new pig model 
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Abstract 
 
Background Tissue engineering of skin with near-normal anatomy is an 
intriguing novel strategy to attack the still unsolved problem of how to ideally cover 
massive full-thickness skin defects. After successful production of large, pig cell-
derived skin analogues, we now aim at developing an appropriate large animal model 
for transplantation studies. 
Materials and methods In four adult Swiss pigs, full-thickness skin defects, 
measuring 7.5x7.5 cm, were surgically created and then shielded against the 
surrounding skin by a new, self-designed silicone chamber. In two animals each, 
Integra dermal regeneration templates or cultured autologous skin analogues, 
respectively, were applied onto the wound bed. A sophisticated shock-absorbing 
dressing was applied for the ensuing 3 weeks. Results were documented 
photographically and histologically. 
Results All animals survived uneventfully. Integra healed in perfectly, 
while the dermo-epidermal skin analogues showed complete take of the dermal 
compartment but spots of missing epidermis. The chamber proved effective in 
precluding (‘‘false positive’’) healing from the wound edges and the special dressing 
efficiently kept the operation site intact and clean for the planned 3 weeks. 
Conclusion We present a novel and valid pig model permitting both 
transplantation of large autologous, laboratory-engineered skin analogues and also 
keeping the site of intervention undisturbed for at least three postoperative weeks. 
Hence, the model will be used for experiments testing whether such large skin 
analogues can restore near normal skin, particularly in the long term. If so, clinical 
application can be envisioned. 
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Introduction 
 
In the preceding companion paper [1] (‘‘Skingineering I’’, published in this 
issue) we have provided detailed information concerning the notorious clinical 
problems when large or massive full-thickness skin defects have to be covered. 
Moreover, we have outlined the rationale for tissue engineering of skin with near 
normal architecture as a potential novel strategy to overcome the mentioned 
problem. 
As a matter of fact, the successful transplantation of small human cell-derived 
skin analogues on athymic rats [2–4] represents an important step forward with 
regard to eventual clinical application of this technique, and it led us to design a 
further experimental series where autologous large scale transplantation of such 
constructs should be tested in a large animal model. In the aforementioned 
companion paper [1] we report on the engineering of pig cell-derived skin substitutes 
suitable for transplantation in a pig model. 
The goal of the present study was to create such a pig model that allows 
standardised large-scale transplantation of laboratory-engineered autologous skin 
analogues. This model, if valid, would then be used for additional preclinical 
experiments looking in detail at various critical aspects including particularly 
functional and cosmetic long-term outcomes of the so reconstituted skin. 
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Materials and methods 
 
Animals 
Adolescent female Swiss pigs (Edelschwein), aged between 2 and 3 months, 
weighing between 30 and 35 kg were housed in a group of 4, received adequate 
quantities of pellet food, yoghurt, and they had access to water ad libitum. They were 
provided with natural day–night cycles. For the purpose of acclimatisation, housing 
began 2 weeks before the start of the experimental phase. Following skin biopsy, 
they were again housed in a group of 4 for another 3 weeks until the formal operative 
procedure. In order to minimise the risk of peer-inflicted damage to the operation site, 
they were thereafter housed individually in neighbouring stalls for the ensuing three 
postoperative weeks until they were killed (details see below). 
 
Silicone chamber 
In order to prevent any spontaneous healing processes from the wound 
edges, a silicone chamber was sutured to the wound edges after creation of the skin 
defect. This device was newly designed (by first author CS) and fabricated (by 
Carsten Linti, ITV Denkendorf, Germany; Fig. 1). 
The transplantation chamber consists of two parts: the chamber, and the cover 
plate. Both parts are made from silicone rubber using a special cast procedure. The 
elastic chamber has hardness (shore A) of 80 after curing and removal from the 
mould. The cover plate is casted from a two-part silicone rubber that cures at room 
temperature. The flexible cover has hardness (shore A) of 25. 
The moulded silicone rubber parts are biocompatible, biostable, and heat 
resistant (200°C) and thus amenable to standard sterilisation processes, e.g. steam 
sterilisation. 
 
Anaesthesia and pain management 
The study protocol was approved by the local Committee for Experimental 
Animal Research (Kantonales Veterinäramt des Kantons Zürich, permission number 
172/2009). 
Prior to all surgical procedures, the pigs were fasted overnight to avoid 
vomiting and aspiration. At first, all animals were sedated by an intramuscular 
injection of a mixture of ketamine 20 mg/kg (Narketan®10 ad us. vet., Vétoquinol AG, 
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Switzerland), azaperone 1.25 mg/kg (StresnilTMad us. vet., Biokema SA, 
Switzerland) and atropine 0.03 mg/kg (Atropine 0.1%: Kantonsapotheke Zürich, 
Switzerland). A venous catheter was placed at the ear to apply propofol (20 mg i.v.) 
(Disoprivan®1% Astra Zeneca, Switzerland) to facilitate intubation. Animals were then 
intubated with an endotracheal tube 8 mm in diameter (AireCufTM, Veterinary 
Endotracheal Tube, all Silicone, Bivona Inc., Indiana, USA) and artificial respiration 
was applied. Anaesthesia was maintained with 2.5% isoflurane (AttaneTMisoflurane 
ad us. vet., Minrad Inc., New York, USA) in oxygen (4.5 l/min). The operation field 
was shaved and the skin was disinfected. 
Anaesthesia was terminated by leaving the animal on oxygen alone. When 
breathing normally, the animal was extubated. Intraoperative analgesia was provided 
by buprenorphine, 0.01 mg/kg (Temgesic®, Essex Chemie AG, Switzerland). Post-
operative analgesia was provided by a transdermal fentanyl matrix patch (50 µg/h) 
(Durogesic® Matrix, Janssen-Cilag AG, Switzerland). Antimicrobial prophylaxis was 
intraoperatively provided by augmentin (600 mg i.v.) (Augmentin®, GlaxoSmithKline 
AG, Switzerland) and continued for 5 days (2x625 mg p.o.). 
 
Operative procedures: 
Biopsy 
Animals were anaesthetised as described above, placed in a left lateral 
position, and disinfected. A strip-shaped (1x10 cm) full-thickness skin biopsy was 
harvested from the right hemiabdomen, and the wound was sutured closed. The 
specimen was then processed as detailed in the twin paper [1]. 
 
Creation of full-thickness skin defect, chamber implantation, and transplantation of 
skin substitutes 
Three weeks post biopsy, animals were again anaesthetised as described, 
placed in prone position, shaved, and disinfected. A square-shaped, 7.5x7.5 cm, full-
thickness skin defect over the midline lumbar area was created. Particular care was 
taken to excise a tissue plate including the entire subcutaneous fat layer so as to 
ascertain all epithelial elements that could have contributed to later epithelialisation 
were removed (Fig. 2a). 
The silicone chamber was then implanted and fixed to the skin edges as 
outlined above (Fig. 2b; n = 4). 
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In two animals, the wound was covered with Integra dermal regeneration 
template (IDRT) in order to obtain immediate and reliable wound protection [5] a 
setting that allows studying the behaviour and the biologic effects of the chamber 
over time. In two other animals, a cultured skin substitute [1] was transplanted in 
order to phenomenologically test graft take (Fig. 2c). All wound sites were covered 
with a soft silver foam dressing. The chamber was closed with a 2-mm-thick silicone 
cover plate (Fig. 2d). With the purpose of protecting the operation sites in an optimal 
way against any sort of potential mechanical trauma over the ensuing 3 weeks, a 
multilayer shock absorber device was installed comprising elements attenuating 
direct as well as sheering forces (Fig. 3) and held in place by a customized garment 
(Fig. 4). 
 
Postoperative management, euthanasia: harvesting and processing of samples 
All animals were individually housed for 3 weeks postoperatively with weekly 
dressing changes and wound site documentations. Thereafter, they were killed by 
intravenous administration of pentobarbital (40–60 mg/kg i.v., Esconarkon, ad us. 
vet., Streuli Pharma AG, Switzerland). After chamber removal, all wound sites were 
completely excised and processed for histology (H&E staining). 
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Results 
 
All pigs survived all experimental procedures and the postoperative phase 
without any significant complications. 
The silicone chambers could be inserted into the wound and sewed in place 
according to the outlined specifications in all animals. Both IDRT and skin analogue 
placement onto the chamber-sheltered wound bed could be performed without any 
problem. Over the ensuing 3 weeks (formal dressing changes after 1 and 2 weeks), 
all the dressings and shock absorber devices remained in place and intact. No 
adverse events, especially bleeding, infection, or traumatic damage, were observed. 
Macroscopically, the chamber did not cause any particular reaction within the 
surrounding tissues like, e.g. a pronounced inflammatory response or excessive 
granulation tissue production, nor did it exhibit any obvious signs of material damage 
like, e.g. deformation, frailty, altered consistency, surface erosion, rust, or colour 
change. 
The IDRT implantation yielded a take of 100% after 1 week and the usually 
encountered peach colour after 3 weeks indicating correct ingrowth and 
vascularization in both animals [6]. No signs of infection and no obvious findings 
indicating any kind of unfavourable interaction of surrounding skin and/or IDRT with 
the chamber were identified (Fig. 5a, b). Histologically, the Integra demonstrated the 
expected and well-documented architecture of a neodermis 3 weeks post 
implantation [6, 7] (Fig. 5c). 
Cultured dermo-epidermal skin substitutes showed a take (determined also 1 
week after transplantation) of the dermal part of nearly 100%, whereas the epidermal 
coverage was estimated between 50 and 60% (Fig. 6a). Histologically (3 weeks post 
transplantation), the dermal compartment demonstrated the well-known features 
characterising a neodermis while the epidermis was well established and correctly 
stratified in some areas (Fig. 6b), whereas in other areas, it was missing. 
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Discussion 
 
The study reported here provides compelling evidence that we have 
established a valid pig model that allows transplantation of large autologous skin 
analogues and also warrants the site of operation be kept undisturbed for at least 3 
weeks after transplantation. The following pivotal profile properties of this large 
animal model deserve to be addressed in more detail.  
First, the model permits transplantation of sizeable grafts measuring 7 9 7 cm. 
This size is suitable for large scale transplantation as it equals for instance the usual 
size of commercially available cultured epidermal autografts for clinical use [8]. Also, 
it has similar dimensions as conventional split thickness skin grafts applied on human 
patients, especially on children [9]. 
Second, autologous transplantation as performed in this experiment parallels 
the future clinical situation where, obviously, only autologous skin analogue-coverage 
of full-thickness skin defects can potentially provide definitive repair in human 
patients. 
Third, the silicone chamber insertion was done for scientific reasons alone: we 
wanted, particularly in view of the future experiments, to explicitly and reliably shield 
the area of interest from any (even partial) false-positive results through healing from 
the wound edges. Overall, the chamber seems to be a valid device in that its 
handling proved to be easy, and it granted the wanted strict compartmentalisation of 
the operation field from the surrounding skin. Moreover, there were no 
macroscopically detectable adverse effects, in particular impaired healing, coming 
from the chamber itself. Of note, IDRT healed in promptly and uneventfully as was to 
be expected, while the much more delicately engineered skin analogues healed with 
spotty epidermal deficits. The random pattern epidermal lack, however, speaks 
against a chamber-associated problem as then, the non-epithelialised areas would 
most likely lay adjacent to the chamber. Yet, the graft healing observed must not be 
over-interpreted in any direction. The goal of this experiment was the establishment 
of a large animal/large graft transplantation model, not the in-depth investigation of 
results after grafting. The latter will be looked at specifically in a next series of formal 
experiments. 
It is noteworthy that our chamber is by far the largest and first rectangular such 
device ever published. All other chambers used for similar purposes were round in 
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shaped and had a maximum diameter or 4 cm [10–12]. In terms of an outlook, we 
figure that the size of this chamber can easily be enlarged, or, alternatively, two or 
more adjacent chambers could be jointly used in the same animal if large enough. 
Fourth, an obligatory requirement of the model is maximum graft protection for 
the first postoperative weeks, when the graft is most vulnerable, and when the animal 
is presumably most annoyed and therefore prone to get rid of the irritation in any way 
possible. Therefore, we chose the back as operation site since the animal cannot 
reach this area with mouth or extremities. Also, rubbing is, even though not entirely 
impossible, rather challenging. Clearly, adequate pain management and individual 
housing, the combination of a closed-up chamber, and a sophisticated overlying 
shock-absorbing dressing proved effective in all animals alike. This aspect cannot be 
overemphasised since all envisioned future experiments rely on long-term 
observation (up to 6–12 months), so grafts must definitely survive the initial phase 
until, when stable enough, they can eventually be left without dressing. 
Finally, pig skin is the closest relative with regard to human skin in terms of 
anatomy and physiology [13, 14]. Therefore, a pig model as the one presented here 
appears to be the most appropriate choice for a preclinical setting in view of future 
skin analogue transplantations in human patients. 
In conclusion, we devised a practicable new pig model allowing transplantation 
of large autologous, laboratory-engineered skin analogues and that, importantly, 
allows keeping the site of intervention clean and intact for the first three postoperative 
weeks. This model appears suitable to reliably conduct those experiments that will 
investigate in detail whether large tissue-engineered skin analogues can consistently 
reconstitute near-normal skin also in the long run. If so, this strategy may eventually 
be introduced into clinical practice. 
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Figures 
 
 
Fig. 1: Silicone chamber. a Silicone chamber designed to prevent spontaneous healing from the 
surrounding skin. The area inside the chamber measures 7x7 cm. b Schematic drawing showing the 
organisation of the wound area with the implanted silicone chamber: 1) muscle including overlying 
fascia, 2) skin analogue, 3) soft silver foam, 4) silicone chamber, 5) pig skin, 6) 2 mm thick silicone 
cover plate to close the chamber, 7) Fixation sutures 
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Fig. 2: Surgical procedure of skin substitute transplantation. a A full-thickness skin defect of 7.5x7.5 
cm, located over the lumbar area is created. b The silicone chamber is implanted and secured by 
fixation sutures. c The cultured skin substitute is transplanted onto the full-thickness wound. d The 
wound is covered with soft silver foam (grey) and a 2-mm-thick silicone cover plate (arrowhead) 
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Fig. 3: Multilayered shock absorber device. Schematic drawing showing the architecture of the device: 
1 muscle including overlying fascia, 2 skin analogue, 3 soft silver foam, 4 silicone chamber, 5 pig skin, 
6 fixation tapes encasing the foam, 7 foam, 8 customized garment 
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Fig. 4: Customized garment. a Schematic drawing of the customized garment for pigs, indicating the 
essential features: 1) two separate zippers, 2) neoprene insertion, 3) border of lambskin upholstery, 4) 
elastic fabric strip. Arrowhead indicates location of shock absorber device under garment. b Picture 
showing the ‘‘custom-made’’ garment on a pig 
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Fig. 5: Dermal substitute integra (IDRT) 3 weeks after transplantation. a Macroscopic view of the 
transplanted IDRT in place. b Macroscopic view of an IDRT-derived neodermis, silicone foil already 
removed. c Haematoxylin and Eosin staining of the excised IDRT (scale bar 100 µm) 
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Fig. 6: Laboratory-grown skin substitute 3 weeks after transplantation. a Macroscopic view of the 
excised skin substitute. Dotted line indicates epithelialised area. Arrowheads indicate locations of 
previously taken punch biopsies. b Haematoxylin and Eosin staining of the excised skin substitute with 
close to normal epidermis (E) and dermis (D) (scale bar 50 µm) 
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5. CONCLUSIONS 
 
In the first publication presented in this work (182) I showed the successful 
combination of collagen type I hydrogels and biodegradable meshes to generate 
dermo-epidermal skin substitutes. Several aspects deserve a detailed comment. 
Both mesh types that were tested in this study did not hamper the survival and 
proliferation of the dermal fibroblasts and epidermal keratinocytes, neither in vitro nor 
in vivo after the transplantation of the skin substitutes onto the back of immuno-
incompetent rats. In vivo, a continuous basement membrane was deposited and 
several suprabasal layers and a stratum corneum were detectable. In addition, 
ingrown blood vessels were observed, ensuring nutrients supply for the skin graft. 
The handling properties of the mesh-reinforced hydrogels were markedly better than 
the handling of non-reinforced hydrogels. This might be an important advantage for 
clinical application. The mesh-reinforced skin substitutes show high potential for the 
treatment of severe full-thickness skin injuries. 
Further studies could evaluate a mesh similar to the knitted mesh but with 
decreased fibre thickness. The mesh tested in this study showed a relatively high 
total fibre volume, which probably could be reduced for skin reconstruction. 
Moreover, it has been shown that resorption of the fibres of the knitted mesh is 
reached after 36 months (183). For the application in skin reconstruction, it might be 
interesting to test the incorporation of a modified version of the knitted mesh with a 
lower fraction of lactide, which would reduce the degradation time. Another point to 
address in subsequent studies is the behaviour of skin substitutes with the 
incorporated meshes in long-term experiments. As the process of wound healing and 
subsequent remodelling of the newly formed tissue takes several months up to years 
(96-99), it would be advantageous to study the in vivo degradation of the meshes 
over a long period and to evaluate the quality of the new skin tissue after this time. 
 
Another aspect was addressed in the second publication of this work (184), in 
which I could show that human amniotic fluid derived cells can substitute for 
fibroblasts and support epidermal growth and stratification in a dermo-epidermal skin 
substitute. This represents the first step towards engineered fetal skin, but without 
the need for harvesting an actual skin biopsy of the fetus. The approach for 
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engineering fetal skin from cells obtained from the amniotic fluid is very appealing, as 
the amniotic fluid is an easily accessible cell source already during pregnancy and 
not only after birth. The human amniocytes integrated into a collagen type I hydrogel, 
instead of the usually used human dermal fibroblasts, were able to substitute for 
fibroblast function with regard to proliferation and differentiation of the epidermis. 
Interestingly, this finding was especially highlighted as skin substitutes with an 
acellular dermal compartment showed poor epidermis survival. This result reinforces 
the need for a mesenchymal compartment that supports the survival, proliferation 
and differentiation of the epidermal keratinocytes and the importance of the cross-talk 
between mesenchyme and epithelium (71,143,185-186). 
After this successful first step towards engineered fetal skin, the next step will 
be to also include fetal keratinocytes. One possibility would be to differentiate 
amniocytes into an epithelial lineage. Alternatively, one could think about isolating 
fetal keratinocytes directly from the human amniotic fluid. If this could be achieved, a 
truly fetal skin analogue could be generated. In addition to the application of a fetal 
engineered skin for the closure of a fetal spina bifida defect, engineered fetal skin 
might also have a potential in the autologous treatment of chronic wounds, as it has 
been shown that fetal skin has an increased wound healing power to adult skin and 
that human amniocytes remain viable and functional over decades of 
cryopreservation (187-188). 
 
Tissue engineering of a dermo-epidermal skin substitute not only has great 
potential and importance in the direct treatment of full-thickness skin injuries; an 
engineered dermo-epidermal skin analogue also has potential applications in the pre-
clinical field. This aspect I investigated in publication III of this thesis (189). The 
development of new medicinal products for the treatment of skin defects requires 
intensive pre-clinical testing. To mimic the clinical application of products designed 
for dermal regeneration as close as possible (100,119,190), we established a model 
that imitates human split-thickness skin and allows for the pre-clinical testing in a 
humanised animal model. The engineered grafts showed very similar characteristics 
and behaviour as human split-thickness skin. One clear difference to split-thickness 
skin was observed regarding the presence of rete ridges in the original human split-
thickness skin, whereas the engineered grafts showed a more flattened dermo-
epidermal junction. The advantage of this new model is its preparation method and 
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easy availability. The preparation can be standardised with regard to cell number, cell 
types, and thickness. This represents an advantage over the original split-thickness 
skin, in which for example the thickness shows high variations even when same 
settings for the dermatome are used, depending on the age of the patient, body 
location but also the executing surgeon. With this model, newly designed products for 
dermal reconstruction can easily be tested in a setting with a human skin substitute, 
but without the need for human split-thickness skin.  
 
It is a major goal of the TBRU to perform clinical trials for the bio-engineered 
dermo-epidermal skin substitute denovoSkin and the bio-engineered dermal 
substitute denovoDerm. For the approval of phase I clinical trials by the federal 
authorities, sufficient and conclusive pre-clinical data on the two products are 
essential requirements. Initially, the in vivo studies with the product (denovoSkin) 
were performed in the immuno-incompetent rat model. This model allows the 
transplantation of round grafts with a diameter of ~3 cm. For additional pre-clinical 
evaluation, in vivo studies on a large animal model, using products exhibiting clinical 
relevant sizes and shapes and applying them in an autologous context, are required. 
Therefore we established a new porcine model in which larger square-shaped grafts 
up of 49 cm2 (7x7 cm) were transplanted. The corresponding results are presented in 
this work in publications IV and V (191-192). Several points deserve detailed 
comments. The pig was chosen as large animal model as it has been shown that the 
porcine skin is the animal skin with most similarities to human skin (180-181). Pigs 
are immuno-competent animals, therefore skin substitutes needed to be generated 
with autologous porcine dermal fibroblasts and epidermal keratinocytes for each 
individual animal in the experiments. Consequently, protocols for the isolation of 
dermal fibroblasts and epidermal keratinocytes had to be adapted to the special 
characteristics of porcine skin, for example the thickness of the skin. Additionally, we 
found that although porcine skin is thought to be the closest to human skin, the 
porcine dermal fibroblasts behaved differently in a collagen type I hydrogel than 
human dermal fibroblasts. The survival and proliferation of the fibroblasts could 
markedly be increased when fibrin was added to the collagen hydrogel. In the rat 
model a modified Fusenig chamber was used to prevent ingrowth of rat tissue over 
the transplanted skin substitute. Similar to this, also for the porcine model a chamber 
was needed that protects the graft. Only with such a chamber it was possible to 
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prove that the wound closed because of the skin substitute and not due to wound 
healing by cells migrating to the wound from the wound borders. The final step for the 
establishment of the new pig model concerned the appropriate wound dressing for 
these animals. Therefore a special dressing garment was developed, customised for 
each animal, to ensure maximal protection for the transplanted skin substitutes. The 
proof of principle of this newly established model was successful, and in the 
meanwhile this model also was used for the transplantation of different variations of 
large, square dermo-epidermal skin substitutes. 
 
The series of publications presented in this work covers different aspects of 
the bio-engineering of autologous human skin grafts and of their clinical application. 
In this sense my work has contributed to the applied (translational) side of cell and 
tissue biology, and to the ultimate goal of developing a complex dermo-epidermal 
skin graft that closely resembles normal human skin and that can be safely and 
conveniently applied on severe full thickness skin wounds, by the surgeon. 
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BSA Bovine serum albumin 
CD Cluster of differentiation 
CK Cytokeratin 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco’s Modified Eagle Medium 
ECM Extracellular matrix 
FCS Fetal calf serum 
FDA United States Food and Drug Administration 
FdA Fluorescein diacetate 
FITC Fluorescein iso-thiocyanate 
GMP Good manufacturing practice 
H&E Haematoxylin & Eosin 
HMB45 Human melanoma black 
IDRT Integra dermal regeneration template® 
K Cytokeratin 
KGF-1 Keratinocyte growth factor 1 
PBS Phosphate buffered saline 
PLGA Poly(lactic-co-glycolic acid) 
TBSA Total body surface area 
TBRU Tissue Biology Research Unit 
TE Tissue engineering 
TRITC Tetramethyl rhodamine iso-thiocyanate 
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